<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml">
   <div xmlns="" tagx="article">
      <head>
         <style type="text/css"> table, tr, td {border : thin;}</style>
         <span class="citation_publisher">Frontiers Media S.A.</span>
         <h2 class="citation-title">Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding
            Protein Region II of Plasmodium Vivax
         </h2>
         <span class="doi">10.3389/fimmu.2015.00348</span>
         <div class="contrib-group">contrib: 
            	  CONT
            	  
            <span class="citation_author">Simone C. de Cassan</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">A. Rushdi Shakri</span>
            <span class="citation_author_institution_ref">2</span>
            <span class="citation_author">David Llewellyn</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Sean C. Elias</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Jee Sun Cho</span>
            <span class="citation_author_institution_ref">3</span>
            <span class="citation_author">Anna L. Goodman</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Jing Jin</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Alexander D. Douglas</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Rossarin Suwanarusk</span>
            <span class="citation_author_institution_ref">3</span>
            <span class="citation_author">François H. Nosten</span>
            <span class="citation_author_institution_ref">5</span>
            <span class="citation_author">Laurent Rénia</span>
            <span class="citation_author_institution_ref">3</span>
            <span class="citation_author">Bruce Russell</span>
            <span class="citation_author_institution_ref">3</span>
            <span class="citation_author">Chetan E. Chitnis</span>
            <span class="citation_author_institution_ref">2</span>
            <span class="citation_author">Simon J. Draper</span>
            <span class="citation_author_institution_ref">1</span>
         </div>
         <span class="email">[simone.decassan@magd.ox.ac.uk]</span>
         <span class="conflict">[]</span>
         <span class="contribs">[]</span>
         <span class="citation_pubdate">[2015-7-08]</span>
         <span class="citation_copyright">[Copyright 2015: de Cassan, Shakri, Llewellyn, Elias, Cho, Goodman, Jin, Douglas, Suwanarusk,
            Nosten, Rénia, Russell, Chitnis and Draper]
         </span>
         <span class="citation_licence">[Licence This is an open-access article distributed under the terms of the Creative
            Commons Attribution License (CC BY). The use, distribution or reproduction in other
            forums is permitted, provided the original author(s) or licensor are credited and
            that the original publication in this journal is cited, in accordance with accepted
            academic practice. No use, distribution or reproduction is permitted which does not
            comply with these terms.]
         </span>
         <span class="citation_funding">[MRC Clinical Training FellowshipG0600424Rhodes TrustWellcome Trust084113/Z/07/ZUK
            Medical Research Council (MRC)G1100086European Community’s Seventh Framework ProgramFP7/2007-2013EVIMalaR242095Singapore
            National Medical Research CouncilNMRC/CBRG/0047/2013Singapore Immunology Network (SIgN)Horizontal
            Program on Infectious DiseasesTechnology and Research (A*STAR, Singapore)The Wellcome
            Trust of Great BritainYong Loo Lin School of MedicineNational University of Singapore
            (Singapore)Malaria Vaccine Initiative (MVI)PATHDepartment of Biotechnology (DBT)Government
            of India (GoI)TATA Innovation Fellowship of DBT, GoILister Institute Research Prize
            FellowUK MRC Career Development FellowG1000527]
         </span>
         <span class="citation_pagecount">[]</span>
         <span class="citation_data">[]</span>
      </head>
      <div id="abstract" tag="abstract">
         <h2>Abstract</h2>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Malaria vaccine development has largely focused on 
            <i>Plasmodium falciparum</i>; however, a reawakening to the importance of 
            <i>Plasmodium vivax</i> has spurred efforts to develop vaccines against this difficult to treat and at times
            severe form of relapsing malaria, which constitutes a significant proportion of human
            malaria cases worldwide. The almost complete dependence of 
            <i>P. vivax</i> red blood cell invasion on the interaction of the 
            <i>P. vivax</i> Duffy-binding protein region II (PvDBP_RII) with the human Duffy antigen receptor
            for chemokines (DARC) makes this antigen an attractive vaccine candidate against blood-stage
            
            <i>P. vivax</i>. Here, we generated both preclinical and clinically compatible adenoviral and poxviral
            vectored vaccine candidates expressing the Salvador I allele of PvDBP_RII – including
            human adenovirus serotype 5 (HAdV5), chimpanzee adenovirus serotype 63 (ChAd63), and
            modified vaccinia virus Ankara (MVA) vectors. We report on the antibody and T cell
            immunogenicity of these vaccines in mice or rabbits, either used alone in a viral
            vectored prime-boost regime or in “mixed-modality” adenovirus prime – protein-in-­adjuvant
            boost regimes (using a recombinant PvDBP_RII protein antigen formulated in Montanide
            <sup>®</sup>ISA720 or Abisco
            <sup>®</sup>100 adjuvants). Antibodies induced by these regimes were found to bind to native parasite
            antigen from 
            <i>P. vivax</i> infected Thai patients and were capable of inhibiting the binding of PvDBP_RII to
            its receptor DARC using an 
            <i>in vitro</i> binding inhibition assay. In recent years, recombinant ChAd63 and MVA vectors have
            been quickly translated into human clinical trials for numerous antigens from 
            <i>P. falciparum</i> as well as a growing number of other pathogens. The vectors reported here are immunogenic
            in small animals, elicit antibodies against PvDBP_RII, and have recently entered clinical
            trials, which will provide the first assessment of the safety and immunogenicity of
            the PvDBP_RII antigen in humans.
         </p>
      </div>
      <div id="S1">
         <h2>Introduction</h2>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Malaria is caused by protozoan parasites of the genus 
            <i>Plasmodium</i>, with five species known to infect humans. Despite extensive efforts with existing
            control measures, the levels of morbidity and mortality associated with this disease
            remain sobering. Historically, vaccine development efforts have almost exclusively
            focused on 
            <i>Plasmodium falciparum</i> – the major causative agent of malarial disease in sub-Saharan Africa (
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>). A second species of parasite, 
            <i>Plasmodium vivax</i>, is the most widespread geographically and thus constitutes a significant proportion
            of human malaria cases worldwide. Although viewed for many decades as a relatively
            inconsequential parasite (
            <span ref-type="bibr" rid="B2">
               <sup>
                  <a href="#B2">2</a>
               </sup>
            </span>), revised estimates suggest 2.5 billion people are living at risk of 
            <i>P. vivax</i> infection in the Americas, as well as Central and South-East Asia (
            <span ref-type="bibr" rid="B3">
               <sup>
                  <a href="#B3">3</a>
               </sup>
            </span>). Recent data also demonstrate that the infection brings a significant burden of
            morbidity and associated mortality, which has been largely under-appreciated in the
            past (
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>). Consequently, the recently revised Malaria Vaccine Technology Roadmap to 2030 (
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>) now recognizes the importance of 
            <i>P. vivax</i> malaria and calls for a vaccine to achieve 75% efficacy over 2 years – equally weighted
            with 
            <i>P. falciparum</i> in an era of renewed political will to control and eradicate this devastating disease.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Different stages of the malaria parasite’s life-cycle can be targeted by subunit immunization.
            In the past, a small handful of pre-erythrocytic and sexual-stage vaccine candidates
            for 
            <i>P. vivax</i>, based on the PvCSP and Pvs25 antigens respectively, have entered early phase clinical
            testing as recombinant protein or long synthetic peptide in adjuvant formulations
            (
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>); none of these candidate formulations, however, remain in active clinical trials.
            Vaccines targeting the asexual blood-stage infection remain an alternative approach,
            aiming to control and clear parasitemia in order to prevent disease and death as well
            as continued transmission. A number of blood-stage malaria vaccine candidates, mainly
            focusing on merozoite ligands involved in erythrocyte invasion, are under development
            for 
            <i>P. falciparum</i> (
            <span ref-type="bibr" rid="B10">
               <sup>
                  <a href="#B10">10</a>
               </sup>
            </span>) but, as yet, no clinical trials of equivalent 
            <i>P. vivax</i> blood-stage candidate vaccines have been reported (
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>).
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Merozoite invasion of erythrocytes is a complex, multi-step process involving many
            receptor–ligand interactions between the parasite and the surface of the host’s red
            blood cell (RBC) (
            <span ref-type="bibr" rid="B12">
               <sup>
                  <a href="#B12">12</a>
               </sup>
            </span>). Invasion of RBCs by 
            <i>P. vixax</i> is restricted to CD71
            <sup>+</sup> reticulocytes (
            <span ref-type="bibr" rid="B13">
               <sup>
                  <a href="#B13">13</a>
               </sup>
            </span>) and commonly uses the interaction of the 
            <i>P. vivax</i> Duffy-binding protein (PvDBP) with the human Duffy antigen receptor for chemokines
            (DARC/Fy) (
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>). Notably, Duffy-negative individuals appear to be protected from blood-stage 
            <i>P. vivax</i> infection, an observation first reported by Miller et al. in 1976 (
            <span ref-type="bibr" rid="B15">
               <sup>
                  <a href="#B15">15</a>
               </sup>
            </span>), confirmed by controlled human infection studies (
            <span ref-type="bibr" rid="B16">
               <sup>
                  <a href="#B16">16</a>
               </sup>
            </span>), and associated geographically with sub-Saharan Africa where 
            <i>P. vivax</i> is largely absent (
            <span ref-type="bibr" rid="B17">
               <sup>
                  <a href="#B17">17</a>
               </sup>
            </span>). Of note, there have been reports of 
            <i>P</i>. 
            <i>vivax</i> isolates that can invade Duffy-negative cells (
            <span ref-type="bibr" rid="B18">
               <sup>
                  <a href="#B18">18</a>
               </sup>
            </span>), with recent sequencing data identifying a gene encoding a PvDBP paralog (
            <span ref-type="bibr" rid="B19">
               <sup>
                  <a href="#B19">19</a>
               </sup>
            </span>). These data suggest that increased expression levels or gene copy number may enable
            invasion into Duffy-negative cells, and further highlight the importance of the PvDBP
            antigen in 
            <i>P</i>. 
            <i>vivax</i> infection.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The micronemal parasite ligands (DBPs or erythrocyte-binding ligands/antigens, EBL/EBA)
            are a family of antigens that are functionally conserved across 
            <i>Plasmodium</i> species. All parasites have at least one EBL, and in many cases these lead to redundancy,
            as observed in 
            <i>P. falciparum</i> (
            <span ref-type="bibr" rid="B20">
               <sup>
                  <a href="#B20">20</a>
               </sup>
            </span>). In the case of 
            <i>P. vivax</i>, the PvDBP gene and its paralog are known to exist (
            <span ref-type="bibr" rid="B19">
               <sup>
                  <a href="#B19">19</a>
               </sup>
            </span>), and genetic knockout of the orthologous simian malaria 
            <i>P. knowlesi</i> DBPα gene prevents invasion of Duffy-positive erythrocytes 
            <i>in vitro</i> (
            <span ref-type="bibr" rid="B21">
               <sup>
                  <a href="#B21">21</a>
               </sup>
            </span>). The receptor-binding domain of PvDBP lies within the conserved, extracellular,
            cysteine-rich region known as region II (PvDBP_RII) (
            <span ref-type="bibr" rid="B22">
               <sup>
                  <a href="#B22">22</a>
               </sup>
            </span>). Antibodies can be induced against this antigen in mice and rhesus macaques using
            recombinant PvDBP_RII protein (rDBP)-in-adjuvant vaccines (
            <span ref-type="bibr" rid="B23">
               <sup>
                  <a href="#B23">23</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B24">
               <sup>
                  <a href="#B24">24</a>
               </sup>
            </span>), and those raised against the 
            <i>P. knowlesi</i> DBPα ortholog can block RBC invasion by this parasite 
            <i>in vitro</i> (
            <span ref-type="bibr" rid="B25">
               <sup>
                  <a href="#B25">25</a>
               </sup>
            </span>). Furthermore, naturally acquired high-titer binding inhibitory antibodies against
            PvDBP_RII have been shown to be associated with reduced risk of 
            <i>P. vivax</i> infection in children residing in an endemic area, as well as lower 
            <i>P. vivax</i> parasite densities following infection (
            <span ref-type="bibr" rid="B26">
               <sup>
                  <a href="#B26">26</a>
               </sup>
            </span>). Thus, to date, the PvDBP_RII adhesin remains the most promising subunit vaccine
            target against 
            <i>P. vivax</i> merozoites; however, this antigen has never been progressed to clinical trials and,
            consequently, no data have existed on the ability of vaccines to induce effective
            immune responses in humans.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Traditionally, recombinant protein vaccines have been developed when seeking to induce
            antibodies by vaccination. Development of such vaccines requires production of the
            antigen in a heterologous expression system followed by formulation in a suitable
            human-compatible adjuvant (
            <span ref-type="bibr" rid="B27">
               <sup>
                  <a href="#B27">27</a>
               </sup>
            </span>). An alternative approach, developed in recent years, has used recombinant viral
            vectored vaccines to deliver proteins of interest with the key aim of inducing antibodies
            in conjunction with T cell responses. A strategy demonstrating the highest degree
            of success to date has utilized a recombinant replication-deficient adenovirus to
            prime an immune response, followed by a booster vaccination (typically 8 weeks later)
            with an attenuated poxvirus recombinant for the same antigen (
            <span ref-type="bibr" rid="B28">
               <sup>
                  <a href="#B28">28</a>
               </sup>
            </span>). This approach has been shown to be reliably immunogenic for high-titer antibody
            induction against a variety of difficult-to-express malaria antigens in mice, rabbits,
            and non-human primates (NHP) (
            <span ref-type="bibr" rid="B29">
               <sup>
                  <a href="#B29">29</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B32">
               <sup>
                  <a href="#B32">32</a>
               </sup>
            </span>). It has also been shown to be safe and immunogenic for the delivery of the 
            <i>P. falciparum</i> blood-stage antigens merozoite surface protein 1 (PfMSP1) and apical membrane antigen
            1 (PfAMA1) in a series of Phase I/IIa clinical trials in healthy adult UK volunteers
            (
            <span ref-type="bibr" rid="B33">
               <sup>
                  <a href="#B33">33</a>
               </sup>
            </span>), and the same viral vectored vaccine technologies are currently entering Phase II/III
            clinical testing in West Africa for Ebola (
            <span ref-type="bibr" rid="B34">
               <sup>
                  <a href="#B34">34</a>
               </sup>
            </span>).
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">An extension of this approach has seen the development of “mixed modality” adenoviral
            prime – protein-in-adjuvant boost (AP) regimes, whereby the two leading subunit vaccine
            delivery platforms are combined, often leading to improved immune responses in mice
            in comparison to the use of either strategy alone (
            <span ref-type="bibr" rid="B35">
               <sup>
                  <a href="#B35">35</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B36">
               <sup>
                  <a href="#B36">36</a>
               </sup>
            </span>). In agreement with these murine data, NHP studies of similar regimes, for candidate
            malaria and HIV-1 vaccines, have also shown particular promise (
            <span ref-type="bibr" rid="B30">
               <sup>
                  <a href="#B30">30</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B37">
               <sup>
                  <a href="#B37">37</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B38">
               <sup>
                  <a href="#B38">38</a>
               </sup>
            </span>). Here, we generated both preclinical and clinically compatible adenoviral and poxviral
            vectored vaccine candidates expressing PvDBP_RII. We report on the humoral and cellular
            immunogenicity of these vaccines in mice or rabbits, either used alone in a viral
            vectored prime-boost regime or in AP regimes using a recombinant protein PvDBP_RII
            antigen administered in adjuvant. Antibodies induced by these regimes were found to
            bind to native parasite antigen from 
            <i>P. vivax</i> infected patients and were capable of inhibiting the binding of PvDBP_RII to its
            receptor DARC 
            <i>in vitro</i>.
         </p>
      </div>
      <div id="S2">
         <h2>Materials and Methods</h2>
         <div id="S2-1">
            <h3>Vaccines and protein</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Viral vectored vaccines expressing PvDBP_RII were generated according to previously
               described methods. Recombinant viruses each express the 984 bp coding sequence of
               region II of the Duffy-binding protein from the Salvador I (
               <i>Sal</i>I) strain of 
               <i>P. vivax</i>, amino acids (αα) 194–521 (GenBank Accession #DQ156512). The PvDBP_RII construct
               was codon optimized for human expression and synthesized by GeneArt (Regensburg, Germany).
               The PvDBP_RII sequence was cloned in frame at the N-terminus to the human tissue plasminogen
               activator (tPA) leader sequence (αα 1–32, GenBank Accession # K03021), which in turn
               was preceded by a Kozak sequence (
               <span ref-type="bibr" rid="B29">
                  <sup>
                     <a href="#B29">29</a>
                  </sup>
               </span>). This transgene cassette was inserted using Gateway
               <sup>®</sup> site specific recombination technology (Invitrogen) into the E1 site of vectors encoding
               the genomes of E1/E3-deleted HAdV5 (
               <span ref-type="bibr" rid="B29">
                  <sup>
                     <a href="#B29">29</a>
                  </sup>
               </span>) and ChAd63 (
               <span ref-type="bibr" rid="B39">
                  <sup>
                     <a href="#B39">39</a>
                  </sup>
               </span>), under the control of the 1.9 kbp CMV promoter (
               <span ref-type="bibr" rid="B40">
                  <sup>
                     <a href="#B40">40</a>
                  </sup>
               </span>). The entire E4 locus of the ChAd63 vector is also replaced with the 
               <i>E4Orf6</i> gene from HAdV5 as previously described (
               <span ref-type="bibr" rid="B39">
                  <sup>
                     <a href="#B39">39</a>
                  </sup>
               </span>). The recombinant adenoviral vaccines were generated and cultured in HEK293 cells,
               purified by CsCl centrifugation, and titered by UV spectrophotometry to give units
               of viral particles (vp/mL) (
               <span ref-type="bibr" rid="B41">
                  <sup>
                     <a href="#B41">41</a>
                  </sup>
               </span>) or by anti-hexon immunostaining of infected T-REx-293 cells to give infectious units
               (ifu/mL) (
               <span ref-type="bibr" rid="B31">
                  <sup>
                     <a href="#B31">31</a>
                  </sup>
               </span>). In the case of modified vaccinia virus Ankara (MVA), the transgene cassette was
               recombined into the thymidine kinase (TK) locus of MVA with expression driven by the
               vaccinia P7.5 early/late promoter. Recombinant MVA viruses were generated as previously
               described – either with an additional GFP marker gene (
               <span ref-type="bibr" rid="B29">
                  <sup>
                     <a href="#B29">29</a>
                  </sup>
               </span>) or without any additional marker (
               <span ref-type="bibr" rid="B35">
                  <sup>
                     <a href="#B35">35</a>
                  </sup>
               </span>). Both MVA vaccines were grown in chicken embryo fibroblasts (CEFs), purified by
               centrifugation through a sucrose cushion, and titered by plaque assay to give plaque-forming
               units (pfu/mL) (
               <span ref-type="bibr" rid="B41">
                  <sup>
                     <a href="#B41">41</a>
                  </sup>
               </span>). Control vectors expressing ovalbumin (OVA) have been described previously (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>).
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Unless otherwise stated, all studies used rDBP produced in 
               <i>Escherichia coli</i> and purified as previously described (
               <span ref-type="bibr" rid="B42">
                  <sup>
                     <a href="#B42">42</a>
                  </sup>
               </span>). Endotoxin levels were measured using the Limulus amebocyte lysate (LAL) gel-clot
               assay according to the manufacturer’s instructions (Salesworth). The endotoxin content
               was &lt;22 EU per 25 μg protein.
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">For the rabbit serum ELISAs, rDBP was produced in suspension HEK293E cells. The construct
               included from N- to C-terminus: the human tPA leader sequence and PvDBP_RII (as for
               the viral vector vaccines), followed by an AviTag biotin acceptor peptide (amino acids
               GLNDIFEAQKIEWHE) followed by a hexa-histidine (His6) tag. Six liters of suspension
               HEK293E cells were transiently transfected as previously described (
               <span ref-type="bibr" rid="B32">
                  <sup>
                     <a href="#B32">32</a>
                  </sup>
               </span>), and culture supernatants were harvested after 4 days when cell viability fell below
               95%. This was then concentrated 20-fold and subsequently buffer exchanged into PBS
               using a Pellicon 3 tangential flow filtration (TFF) system (Millipore, Herts, UK).
               Purification consisted of a cobalt-based immobilized metal affinity chromatography
               (IMAC) – Hitrap TALON crude (GE Healthcare, Bucks, UK) and a size exclusion chromatography
               (SEC) – SepFast GF-HS-L 16/1000 (Biotoolomics, Durham, UK). The purified protein was
               quantified by Nanodrop (Thermo Fisher Scientific, Leics, UK) and stored at −80°C until
               further use.
            </p>
         </div>
         <div id="S2-2">
            <h3>Vaccine adjuvants</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Adjuvants used in this study were dosed and prepared in low phosphate PBS (&lt;5mM) (Gibco-Invitrogen,
               UK) as previously described (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>). In brief, Abisco
               <sup>®</sup>100 (Isconova, Sweden) (12 μg/dose) was gently mixed with antigen in PBS; and Montanide
               <sup>®</sup>ISA720 (Seppic, France) was emulsified using a T10 ULTRA-TURRAX
               <sup>®</sup> (IKA
               <sup>®</sup>) homogenizer under sterile conditions at 25,000 rpm for 6 min, keeping the sample
               on ice in a ratio of 3:7 (antigen:adjuvant). All vaccines were kept on ice until administration.
               Abisco
               <sup>®</sup>100 is an ISCOMatrix containing phosphatidyl choline phospholipid, cholesterol, and
               saponins purified from the tree 
               <i>Quillaja saponaria</i> Molina – a mixture of Matrix A and Matrix C (containing the QS7 and QS21 fractions
               respectively) purified from the Quil-A extract. Montanide
               <sup>®</sup>ISA720, an oil-in-water emulsion, is produced with squalene oil and a refined surfactant
               based on mannide oleate.
            </p>
         </div>
         <div id="S2-3">
            <h3>Animals and immunizations</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">All procedures on mice were performed in accordance with the terms of the UK Animals
               (Scientific Procedures) Act Project License and were approved by the University of
               Oxford Animal Welfare and Ethical Review Body. Six to eight-week-old female BALB/c
               (H-2
               <sup>d</sup>) mice were purchased from Harlan Laboratories (Oxfordshire, UK) or bred at the Wellcome
               Trust Centre for Human Genetics (Oxford, UK). Mice were anesthetized before immunization
               with Isoflo (Abbot Animal Health, UK), and all immunizations were administered intramuscularly
               (i.m.) with vaccine divided equally into each 
               <i>musculus tibialis</i>. Immunization doses and regimes are explained in the text and figure legends. Serum
               was harvested at stated time-points from tail vein bleeds or by exsanguination under
               terminal anesthesia at the final harvest time-point.
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rabbit work was conducted by Biogenes (Germany). Female ZiKa rabbits (
               <i>n</i> = 4) were immunized i.m. with 4 × 10
               <sup>8</sup> ifu HAdV5-PvDBP_RII on day 0 and 5 × 10
               <sup>7</sup> pfu MVA-PvDBP_RII (ML) on day 56. Two control rabbits received the same doses and
               regime of viral vectors encoding OVA (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>). Serum was harvested before immunization (day 0) and 28, 56, and 70 days post adenovirus
               administration.
            </p>
         </div>
         <div id="S2-4">
            <h3>Enzyme linked immunosorbent assay</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Unless stated otherwise, mouse IgG ELISAs were carried out using a standardized ELISA
               according to previously described methodology (
               <span ref-type="bibr" rid="B43">
                  <sup>
                     <a href="#B43">43</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B44">
                  <sup>
                     <a href="#B44">44</a>
                  </sup>
               </span>) and using a reference sample generated from high-titer sera pooled from PvDBP_RII
               vaccinated mice. A 1:9000 dilution of the reference sample gave an OD
               <div tagxxx="sub">405</div> = 1.0, and thus this reference serum was taken to be 9000 arbitrary units (AU). Test
               samples were diluted appropriately so that their optical density 405 nm (OD
               <div tagxxx="sub">405</div>) could be read off the linear part of the reference curve. Alternatively, and where
               stated in the text, endpoint ELISAs were performed as described previously (
               <span ref-type="bibr" rid="B29">
                  <sup>
                     <a href="#B29">29</a>
                  </sup>
               </span>). In brief, Nunc-Immuno Maxisorp plates (Thermo Scientific, UK) were coated overnight
               at room temperature (RT) with PvDBP_RII protein. Plates were washed with PBS/0.05%
               Tween 20 (PBS/T) and blocked for 1 h with 10% skimmed milk powder in PBS/T. Serum
               samples were diluted in PBS/T and added in duplicate, with threefold dilutions down
               the plate, before incubation for 2 h at RT. After washing, goat anti-mouse total IgG
               conjugated to alkaline phosphatase (Sigma Aldrich, UK) was added for 1 h at RT, followed
               by a final wash, and then addition of 1 mg/mL 
               <i>p-</i>nitrophenylphosphate in diethanolamine buffer (Pierce, UK) as developing substrate.
               OD
               <div tagxxx="sub">405</div> was read using a Model 550 Microplate Reader (Bio-Rad, UK). Serum antibody endpoint
               titers were taken as the 
               <i>x</i>-axis intercept of the dilution curve at an absorbance value 3 SDs greater than the
               OD
               <div tagxxx="sub">405</div> for naïve mouse serum. A standard positive serum sample and naïve serum sample were
               included as controls for each assay. The same methodology was used for rabbit endpoint
               ELISAs except that PvDBP_RII protein was produced in HEK293E cells and an anti-rabbit
               IgG secondary was used as described previously (
               <span ref-type="bibr" rid="B45">
                  <sup>
                     <a href="#B45">45</a>
                  </sup>
               </span>).
            </p>
         </div>
         <div id="S2-5">
            <h3>Isotype ELISA</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">To measure antigen-specific IgG1 and IgG2a responses, plates were coated as before
               but at a concentration of 1 μg/mL protein. After blocking, serum diluted 1:1000 in
               PBS/T was added in duplicate to the plate for 2 h at RT. Plates were then washed and
               either biotin anti-mouse IgG1 or IgG2a (BD biosciences) at a 1:5000 dilution were
               added to the test plates for 1 h at RT. Following washing and a 30 min incubation
               with Extravidin Alkaline Phosphatase (Sigma Aldrich, UK), plates were developed as
               for total IgG ELISA. A standard positive serum sample and naïve mouse serum sample
               were included as controls.
            </p>
         </div>
         <div id="S2-6">
            <h3>Isolation of splenocytes</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Splenocytes were prepared fresh from mouse spleens as previously described (
               <span ref-type="bibr" rid="B46">
                  <sup>
                     <a href="#B46">46</a>
                  </sup>
               </span>). Where stated in the text, samples were also frozen down in 1 mL aliquots fetal
               calf serum (FCS) with 10% DMSO and stored at −80°C. Prior to use, frozen samples were
               thawed and immediately added to pre-warmed media [minimal essential media (MEM) α-modification
               containing 4 mM 
               <div tagxxx="sc">l</div>-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 μM β-mercaptoethanol,
               and 10% heat-inactivated FCS]. Cells were then washed twice with media and allowed
               to rest at 37°C, 5% CO
               <div tagxxx="sub">2</div> in a humidified incubator for 1 h before use.
            </p>
         </div>
         <div id="S2-7">
            <h3>
               <i>Ex vivo</i> IFN-γ spleen ELISpot
            </h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-γ ELISpots were performed using splenocytes as previously described (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>). In brief, spleen cells were re-suspended at 1 × 10
               <sup>7</sup> cells/mL in complete medium and plated at 50 μL cells per well. Fifty microliters
               complete medium alone was added to control wells, and 50 μL re-stimulation in complete
               medium was added to duplicate test wells as follows: rDBP at a final concentration
               5 μg/mL; or a pool of 32 20mer peptides (NEO Peptide, USA) overlapping by 10 amino
               acids (except the final peptide, number 32, was an 18mer) corresponding to the whole
               of the PvDBP_RII coding sequence at a final concentration 5 μg/mL each peptide; or
               individual peptides used at 5 μg/mL final concentration. Results are expressed as
               spot forming units (SFU) per million splenocytes. Background responses in media-only
               wells were subtracted from those measured in re-stimulated wells.
            </p>
         </div>
         <div id="S2-8">
            <h3>Intracellular cytokine staining</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mouse splenocytes were restimulated for 5 h at 37°C in the presence of GolgiPlug (BD
               Biosciences) and peptides [single or overlapping peptides (OLP) pool] specific for
               PvDBP_RII at a final concentration of 1 μg/mL per peptide (or no peptide unstimulated
               control), before storage at 4°C overnight. Cells were then incubated for 15 min in
               the presence of anti-mouse CD16/CD32 (Fc-block) before surface staining for 30 min,
               with anti-mouse CD8α-PerCP-Cy5.5 (clone 53-6.7) and CD4-Pacific Blue (clone GK1.5)
               and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 405 nm excitation (Invitrogen).
               Permeabilization was performed using Cytofix/Cytoperm solution (BD Biosciences) according
               to the manufacturer’s instructions. Cells were stained intracellularly for 30 min
               with anti-mouse IFN-γ-Alexa Fluor 647 (clone XMG1.2). All incubations were performed
               at 4°C with staining antibodies from eBioscience. Cells were resuspended in 1% formalin
               solution and analyzed using a LSRII flow cytometer (BD Biosciences). Data were analyzed
               using FlowJo version 9.7.5. Background responses from the unstimulated control cells
               were typically 0.05%.
            </p>
         </div>
         <div id="S2-9">
            <h3>Binding inhibition assay</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A binding inhibition assay was carried out to study the ability of antibodies raised
               in mice against PvDBP_RII to inhibit the binding of this protein to its receptor DARC,
               as previously described (
               <span ref-type="bibr" rid="B42">
                  <sup>
                     <a href="#B42">42</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B47">
                  <sup>
                     <a href="#B47">47</a>
                  </sup>
               </span>). Sera diluted as indicated were pre-incubated with 0.025 μg/mL of recombinant PvDBP_RII
               (
               <i>Sal</i>I strain sequence) for 1 h at RT before adding to ELISA plates pre-coated with recombinant
               DARC (nDARC-Fc; N-terminal extracellular 60 amino acids of DARC fused to Fc region
               of human IgG) protein at 1 μg/mL. Bound PvDBP_RII was detected with rabbit polyclonal
               anti-PvDBP_RII sera (1:4000 dilution), followed by goat anti-rabbit IgG HRP-conjugated
               antibodies (1:6000 dilution). A standard curve generated using binding of PvDBP_RII
               (0.002–0.025 μg/mL) to DARC was used to convert OD values into amount of protein bound
               in each well. Percent inhibition was calculated as 100% minus % protein bound. A positive
               control serum (raised in mice against PvDBP_RII using Freund’s adjuvant) and a negative
               control serum (from naïve mice) were included in each assay. The negative control
               sample had a median of 4% binding inhibition across all replicates tested across the
               different dilutions.
            </p>
         </div>
         <div id="S2-10">
            <h3>Indirect immunofluorescence assay</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
               <i>Plasmodium vivax</i>-infected blood was collected from malaria patients attending the clinics of the Shoklo
               Malaria Research Unit (SMRU), Mae Sot region northwest of Thailand, after written
               informed consent (OXTREC 027-025; University of Oxford, Centre for Clinical Vaccinology
               and Tropical Medicine, Oxford, UK). The 
               <i>P. vivax</i>-infected erythrocytes were cultured to the late schizont stage prior to being concentrated
               and washed as previously described (
               <span ref-type="bibr" rid="B48">
                  <sup>
                     <a href="#B48">48</a>
                  </sup>
               </span>), before being smeared onto glass slides, air dried, and fixed with cold acetone
               for 20 min. For the immunofluorescence assays (IFAs), the thin-smear preparations
               were blocked with 1% Casein, 10% goat serum in PBS for 1 h at RT. Mouse sera (diluted
               1:50) or rabbit sera (diluted 1:100) were applied to the slides and incubated for
               1.5 h at 37.5°C or 1 h at RT in a humidified incubator, respectively. The slides were
               then washed three times with PBS before the addition of anti-mouse or anti-rabbit
               IgG conjugated to Alexa Fluor 488 (Molecular Probes) diluted 1:100 (mouse) or 1:1000
               (rabbit) with 1% Casein, 10% goat serum in PBS for 1 h at RT, and mounted with Vectashield
               (Vectorlabs) with DAPI (4′,6-diamidino-2-phenylindole) (Invitrogen). Binding was visualized
               using a Nikon TS 100 epifluorescence microscope.
            </p>
         </div>
         <div id="S2-11">
            <h3>Statistical analysis</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">All statistical analysis was carried out using Prism version 5.04 (Graphpad, USA).
               For non-parametric data, a Kruskal–Wallis test with Dunn’s multiple comparison post-test
               was used to compare more than two groups, and a Mann–Whitney 
               <i>U</i>-test was used to compare two groups. A two-way ANOVA with Bonferroni’s multiple comparison
               post-test was used to explore the effect of two variables. 
               <i>P</i> &lt; 0.05 was considered significant.
            </p>
         </div>
      </div>
      <div id="S3">
         <h2>Results</h2>
         <div id="S3-1">
            <h3>Antibody responses induced by adenovirus-MVA PvDBP_RII vaccines</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Viral vectored vaccines, when used in a heterologous prime-boost regime, have previously
               been shown in various preclinical animal models to induce functional antigen-specific
               antibody responses targeting 
               <i>P. falciparum</i> antigens, such as PfMSP1, PfAMA1, PfRH5, and Pfs25 (
               <span ref-type="bibr" rid="B30">
                  <sup>
                     <a href="#B30">30</a>
                  </sup>
               </span>–
               <span ref-type="bibr" rid="B32">
                  <sup>
                     <a href="#B32">32</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B45">
                  <sup>
                     <a href="#B45">45</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B49">
                  <sup>
                     <a href="#B49">49</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B50">
                  <sup>
                     <a href="#B50">50</a>
                  </sup>
               </span>). Here, we initially generated recombinant viral vectors for use in preclinical proof-of-concept
               studies: a human adenovirus serotype 5 (HAdV5) vector expressing PvDBP_RII, and a
               MVA expressing the same PvDBP_RII antigen, as well as a selectable marker (green fluorescent
               protein, GFP) under the control of separate promoters.
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BALB/c mice were immunized with 10
               <sup>10</sup> viral particles (vp) HAdV5-PvDBP_RII and boosted 8 weeks later with 10
               <sup>7</sup> plaque forming units (pfu) MVA-PvDBP_RII (GFP). Total IgG titers were assayed against
               rDBP by ELISA in serum 2 weeks after each immunization and before the boost. Antigen-specific
               antibody responses were detected 14 days post-HAdV5 immunization (Figure 
               <span ref-type="fig" rid="F1">1</span>A). These responses continued to increase by day 55 and were boosted by MVA vaccine
               administration on day 56. These responses confirmed the ability of viral vectored
               vaccines to induce anti-PvDBP_RII IgG.
            </p>
            <div tagxxx="fig">
               <span class="label">Figure 1</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>Humoral responses induced by viral vectored and protein vaccines targeting PvDBP_RII</b>. 
                     <b>(A)</b> BALB/c mice (
                     <i>n</i> = 5) were immunized with 10
                     <sup>10</sup> vp of a recombinant HAdV5 expressing PvDBP_RII, and boosted 8 weeks later with 10
                     <sup>7</sup> pfu of a recombinant MVA expressing PvDBP_RII and the selectable marker GFP. 
                     <b>(B)</b> BALB/c mice (
                     <i>n</i> = 6/group) were immunized with 1.5 × 10
                     <sup>8</sup> ifu of either HAdV5 or ChAd63 expressing PvDBP_RII, and 8 weeks later, mice were
                     boosted with 10
                     <sup>7</sup> pfu MVA-PvDBP_RII either expressing the selectable marker GFP or no marker (ML).
                     
                     <b>(C)</b> BALB/c mice (
                     <i>n</i> = 4–6/group) were immunized with the regime outlined in 
                     <b>(A)</b> (AM), or immunized three times i.m. 3 weeks apart with 10 μg of PvDBP_RII protein
                     formulated with the specified adjuvant (PPP), or primed i.m. with 10
                     <sup>10</sup> vp of HAdV5-PvDBP_RII and boosted 8 weeks later i.m. with 10 μg of PvDBP_RII protein
                     formulated with adjuvant (AP). In all panels, serum IgG titers were measured in arbitrary
                     units (AU) against PvDBP_RII protein by ELISA 2 weeks after each immunization (day
                     14 and 70) and before the boost (day 55) in 
                     <b>(A,B)</b>, and 2 weeks after the second immunization (PP) or final immunization (PPP, AP, AM)
                     in 
                     <b>(C)</b>. In 
                     <b>(C)</b>, responses following two immunizations are shown with open symbols (PP, AP, AM) and
                     after three immunizations with closed symbols (PPP). ND, not done. Median and individual
                     data points are shown. The dotted line indicates the threshold for responses above
                     background in 
                     <b>(B)</b> determined using serum taken from the mice prior to any immunization. The same cut-off
                     would apply in 
                     <b>(A)</b> but is not indicated.
                  </p>
               </caption>
               <div tagxxx="graphic"></div>
            </div>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Owing to high levels of pre-existing immunity to HAdV5 within the human population,
               other adenoviral vectors have been sought for clinical vaccine development (
               <span ref-type="bibr" rid="B51">
                  <sup>
                     <a href="#B51">51</a>
                  </sup>
               </span>). Simian adenoviruses, against which there is typically minimal neutralization by
               human sera, have emerged as a leading alternative (
               <span ref-type="bibr" rid="B28">
                  <sup>
                     <a href="#B28">28</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B52">
                  <sup>
                     <a href="#B52">52</a>
                  </sup>
               </span>). In particular, the chimpanzee adenovirus serotype 63 (ChAd63) has been found to
               induce strong cellular and humoral immune responses, comparable to HAdV5 in animal
               models, and has also been shown to be safe and highly immunogenic in clinical trials
               (
               <span ref-type="bibr" rid="B44">
                  <sup>
                     <a href="#B44">44</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B53">
                  <sup>
                     <a href="#B53">53</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B54">
                  <sup>
                     <a href="#B54">54</a>
                  </sup>
               </span>). Having demonstrated the humoral immunogenicity of the preclinical HAdV5 and MVA
               vectors, we next sought to do the same with clinically compatible vectors and undertook
               a comparative immunogenicity study. We thus generated a ChAd63 vector expressing PvDBP_RII,
               as well as a recombinant MVA-PvDBP_RII vector lacking the GFP marker gene (“markerless”,
               ML) before undertaking a comparative immunogenicity assessment. Adenoviral vectors
               may be titered by either assessing vp or infectious units (ifu). Unlike vp counts,
               the ifu titer only measures virus capable of infecting cells, and therefore dosing
               based on ifu provides the most appropriate means for comparing adenoviral vector immunogenicity
               (
               <span ref-type="bibr" rid="B39">
                  <sup>
                     <a href="#B39">39</a>
                  </sup>
               </span>).
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BALB/c mice were thus immunized with 1.5 × 10
               <sup>8</sup> ifu HAdV5 or ChAd63 encoding PvDBP_RII, and 8 weeks later were boosted with 10
               <sup>7 </sup>pfu MVA-PvDBP_RII (GFP) or MVA-PvDBP_RII (ML). As before, total IgG titers were assayed
               in serum 2 weeks after each immunization and before the boost by ELISA against PvDBP_RII
               protein. Following immunization with ChAd63-PvDBP_RII, the IgG responses followed
               the same antibody kinetic as observed with HAdV5. Similarly, there was no significant
               difference between total IgG titers 14 days after the priming immunization with HAdV5
               or ChAd63 (
               <i>P</i> = 0.09, Mann–Whitney test, 
               <i>n</i> = 6 per group), although there was a trend toward lower antibody titers with ChAd63
               (Figure 
               <span ref-type="fig" rid="F1">1</span>B). By day 55, this difference had become significant when IgG titers were compared
               between mice receiving HAdV5 versus ChAd63 (
               <i>P</i> = 0.0002, Mann–Whitney test, 
               <i>n</i> = 6 versus 9); however, after the MVA boost immunization, there were no significant
               differences observed in the IgG titers at day 70 following the three different regimes
               tested (
               <i>P</i> = 0.11, Kruskal–Wallis test with Dunn’s multiple comparison post-test). These data
               showed the immunogenicity of the ChAd63 vector as well as the comparable immunogenicity
               of the markerless and GFP-expressing MVAs.
            </p>
         </div>
         <div id="S3-2">
            <h3>Antibody responses induced by adenovirus-protein PvDBP_RII vaccines</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">We next assessed the ability of a “mixed modality” immunization approach (
               <span ref-type="bibr" rid="B28">
                  <sup>
                     <a href="#B28">28</a>
                  </sup>
               </span>) to maximize antibody induction by subunit vaccination. Adenovirus-protein/adjuvant
               (AP) and protein/adjuvant-only (PPP) regimes have previously been shown to induce
               higher titer antibody responses than the adenovirus-MVA regime (AM) in mice (
               <span ref-type="bibr" rid="B35">
                  <sup>
                     <a href="#B35">35</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>), rhesus macaques (
               <span ref-type="bibr" rid="B30">
                  <sup>
                     <a href="#B30">30</a>
                  </sup>
               </span>), and humans (
               <span ref-type="bibr" rid="B55">
                  <sup>
                     <a href="#B55">55</a>
                  </sup>
               </span>). BALB/c mice were thus immunized with 10
               <sup>10</sup> vp HAdV5-PvDBP_RII and boosted 8 weeks later with 10 μg of PvDBP_RII protein (AP)
               formulated in two different adjuvants – Montanide
               <sup>®</sup>ISA720 and Abisco
               <sup>®</sup>100. Both adjuvants have previously been shown to induce high-titer responses in both
               AP and PPP regimes when tested with the model antigen OVA (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>). For comparison, mice were also immunized three times, 21 days apart, with 10 μg
               PvDBP_RII protein (PPP) formulated in the same adjuvants, or with HAdV5-MVA (AM) as
               before. Total IgG titers were assayed in serum 2 weeks after the second protein immunization
               (PP) in the PPP groups, and after the final immunization in all groups by ELISA against
               PvDBP_RII protein (Figure 
               <span ref-type="fig" rid="F1">1</span>C). Following three protein immunizations (PPP), there were no differences between
               the two adjuvants tested, although after two protein vaccinations (PP) Abisco
               <sup>®</sup>100 performed slightly better than Montanide
               <sup>®</sup>ISA720. Moreover, similar to previous studies using other antigens, median anti-PvDBP_RII
               IgG titers were over 10-fold higher in mice immunized with the AP and PPP regimes
               in comparison to those immunized with the AM regime [reaching significance for PPP
               (Abisco
               <sup>®</sup>100) versus AM following Kruskal–Wallis test with Dunn’s multiple comparison post-test,
               
               <i>P</i> &lt; 0.01]. Overall, these data confirmed that the highest titer IgG responses against
               PvDBP_RII in mice can be achieved in the context of either PPP or AP immunization
               regimes in conjunction with relatively “strong” adjuvants.
            </p>
         </div>
         <div id="S3-3">
            <h3>IgG isotype responses induced by PvDBP_RII vaccination</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">To further characterize the vaccine-induced antibody responses against PvDBP_RII,
               serum IgG1 and IgG2a isotype responses were assessed by ELISA 2 weeks after the final
               vaccination in mice immunized with the AP, PPP, and AM regimes outlined previously.
               Both antibody subclasses were induced by each regime tested (Figure 
               <span ref-type="fig" rid="F2">2</span>A); however, as previously reported (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>), a more balanced isotype response was induced in the context of AP and AM immunization
               – most likely reflecting stronger polarization toward Th1-type IgG2a when using a
               viral vector. A similar effect was observed for the Abisco
               <sup>®</sup>100 adjuvant in the context of PPP immunization, in comparison to protein formulation
               in Montanide
               <sup>®</sup>ISA720 which resulted in a dominant Th2-type IgG1 response. Analysis of the log isotype
               IgG1:IgG2a ratio showed a significant effect of immunization regime (AP versus PPP),
               consistent with previously published data using other antigens (
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>), and conferring greater induction of IgG2a following a viral vectored priming vaccination
               (
               <i>P</i> = 0.005, two way-ANOVA) (Figure 
               <span ref-type="fig" rid="F2">2</span>B). The effect of adjuvant was also significant (
               <i>P</i> = 0.009), driven by Abisco
               <sup>®</sup>100, which induced comparable levels of IgG2a in the context of both the AP and PPP
               regimes.
            </p>
            <div tagxxx="fig">
               <span class="label">Figure 2</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>IgG isotype responses induced by PvDBP_RII vaccination</b>. BALB/c mice (
                     <i>n</i> = 4–6/group) were immunized with the AM, AP, or PPP regimes as described in Figure
                     
                     <span ref-type="fig" rid="F1">1</span>C. IgG1 and IgG2a antibody responses were measured in the serum 2 weeks after the
                     last immunization by ELISA against PvDBP_RII protein. 
                     <b>(A)</b> Individual and median responses are shown. The dotted line indicates the threshold
                     for responses above background determined using serum taken from the mice prior to
                     any immunization. 
                     <b>(B)</b> IgG1:IgG2a ratios were calculated and log transformed for the AP and PPP groups.
                     Individual and median responses are shown.
                  </p>
               </caption>
               <div tagxxx="graphic"></div>
            </div>
         </div>
         <div id="S3-4">
            <h3>T cell immunogenicity of PvDBP_RII vaccines</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The induction of CD4
               <sup>+</sup> T cell responses is also an important consideration in the context of antibody-inducing
               vaccination. Such responses are necessary to help B cell responses, and drive class-switching
               and somatic hypermutation within the germinal centers (
               <span ref-type="bibr" rid="B56">
                  <sup>
                     <a href="#B56">56</a>
                  </sup>
               </span>). We therefore undertook an assessment of the ability of the different immunization
               regimes to induce PvDBP_RII-specific T cell responses. Initially, responses were assessed
               using an 
               <i>ex vivo</i> IFN-γ ELISpot assay. Spleens were harvested from mice previously immunized with the
               AP and PPP PvDBP_RII regimes, during the resting memory phase (10 weeks after the
               final immunization). Splenocytes were re-stimulated for 18 h with rDBP and IFN-γ secretion
               assessed (Figure 
               <span ref-type="fig" rid="F3">3</span>A). At this late memory time-point, moderate-to-low T cell responses were observed
               with a comparable magnitude irrespective of immunization regime or adjuvant. Median
               responses of 328 and 199 SFU/million splenocytes were induced by PPP immunization
               using Abisco
               <sup>®</sup>100 and Montanide
               <sup>®</sup>ISA720, respectively, while the AP regimes using the same adjuvants showed median
               responses of 184 and 297 SFU/million splenocytes.
            </p>
            <div tagxxx="fig">
               <span class="label">Figure 3</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>T cell responses induced by viral vectored and protein vaccines targeting PvDBP_RII</b>. 
                     <b>(A)</b> BALB/c mice (
                     <i>n</i> = 4–5/group) were immunized with AP and PPP regimes against PvDBP_RII as described
                     in Figure 
                     <span ref-type="fig" rid="F1">1</span>C. Ten weeks after the last immunization, spleens were harvested and T cell responses
                     were measured from frozen spleen samples by 
                     <i>ex vivo</i> IFN-γ ELISpot following re-stimulation with 5 μg/mL recombinant PvDBP_RII protein
                     (rDBP). Median and individual data points are shown. 
                     <b>(B)</b> BALB/c mice (
                     <i>n</i> = 6) were immunized with HAdV5-PvDBP_RII and boosted 8 weeks later with MVA-PvDBP_RII
                     using doses as in Figure 
                     <span ref-type="fig" rid="F1">1</span>B. Two weeks after the last immunization, splenic T cell responses were measured by
                     
                     <i>ex vivo</i> IFN-γ ELISpot following re-stimulation with 5 μg/mL rDBP or 2 μg/mL OLP. Median and
                     individual responses are shown. 
                     <b>(C)</b> Splenic T cell responses were measured from frozen samples in the mice reported in
                     Figure 
                     <span ref-type="fig" rid="F1">1</span>B 2 weeks after the boost immunization and using OLP. Median and individual responses
                     are shown. 
                     <b>(D)</b> BALB/c mice were immunized with 1.5 × 10
                     <sup>8</sup> ifu HAdV5-PvDBP_RII and 8 weeks later were boosted with 10
                     <sup>7</sup> pfu MVA-PvDBP_RII (GFP). Splenic T cell responses were measured from frozen spleen
                     samples harvested 2 weeks post-boost and following re-stimulation with 5 μg/mL individual
                     peptides (1–32) or the OLP pool control. Results from a representative mouse are shown.
                     
                     <b>(E)</b> BALB/c mice were immunized with 1 × 10
                     <sup>8</sup> ifu HAdV5-PvDBP_RII and 8 weeks later were boosted with 10
                     <sup>7</sup> pfu MVA-PvDBP_RII. Spleens were harvested 15 days post-boost. Intracellular cytokine
                     staining followed by flow cytometric analysis showed the IFN-γ responses induced to
                     the OLP pool and the three strongest peptides (Table 
                     <span ref-type="table" rid="T1">
                        <a href="#T1">1</a>
                     </span>) were from CD4
                     <sup>+</sup> cells. Cells were gated on lymphocytes, and then (top row) singlets by forward scatter
                     height (FSC-H) versus area (FSC-A), then live cells (dead cell marker versus side
                     scatter area, SSC-A), and then CD4 versus CD8. Representative plots (bottom row) of
                     IFN-γ versus SSC-A from CD4
                     <sup>+</sup> gated cells are shown from one mouse following no stimulation (Unstim) or re-stimulation
                     with the OLP pool or peptide 14 (P14).
                  </p>
               </caption>
               <div tagxxx="graphic"></div>
            </div>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In contrast to the observations here, previous studies with other antigens have generally
               shown stronger cellular responses when using viral vectored delivery platforms in
               comparison to protein-in-adjuvant (
               <span ref-type="bibr" rid="B35">
                  <sup>
                     <a href="#B35">35</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B36">
                  <sup>
                     <a href="#B36">36</a>
                  </sup>
               </span>). The previous assay had also used recombinant protein for the re-stimulation phase,
               and not OLP which are most commonly used for such T cell assays. Protein antigen cannot
               bind directly to MHC molecules displayed on the surface of antigen presenting cells
               (APCs), and instead is most likely processed into peptides by the exogenous pathway
               before these are loaded onto MHC class II molecules. Re-stimulation with recombinant
               protein is thus unlikely to measure CD8
               <sup>+</sup> T cell responses which require peptide presentation on MHC class I molecules. We
               therefore next sought to compare this assay to one using OLP, spanning the whole of
               the PvDBP_RII antigen. To maximize cellular responses, mice were immunized with the
               HAdV5–MVA regime, and spleens were harvested from mice 2 weeks after the MVA immunization.
               Splenocytes were subsequently re-stimulated with either OLP or rDBP in the 
               <i>ex vivo</i> IFN-γ ELIspot assay (Figure 
               <span ref-type="fig" rid="F3">3</span>B). A median response of 244 and 254 SFU/million splenocytes was observed with OLP
               and rDBP, respectively (
               <i>P</i> = 0.59, Mann–Whitney 
               <i>U</i>-test). These data suggest that the two stimuli perform comparably, perhaps indicating
               minimal CD8
               <sup>+</sup> T cell induction against this antigen in BALB/c mice. Given we previously compared
               antigen-specific IgG immunogenicity from the different adenoviral and MVA vaccines,
               we also assessed the cellular immunogenicity across the different regimes previously
               tested in Figure 
               <span ref-type="fig" rid="F1">1</span>B. As with the humoral immunogenicity, no significant differences were observed between
               the groups receiving an HAdV5 versus ChAd63 prime, or the GFP marker versus “markerless”
               MVA boost (
               <i>P</i> = 0.63, Kruskal–Wallis test) (Figure 
               <span ref-type="fig" rid="F3">3</span>C).
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">To further characterize the T cell response to PvDBP_RII, the OLP were used to map
               H-2
               <sup>d</sup> T cell epitopes in these BALB/c mice. Each of the 32 individual peptides in the OLP
               pool were tested individually, and three peptides (7, 8, and 14) induced responses
               consistently above background in the tested spleen samples (Table 
               <span ref-type="table" rid="T1">
                  <a href="#T1">1</a>
               </span> and Figure 
               <span ref-type="fig" rid="F3">3</span>D). Responses were consistently strongest for peptide 14, accounting for most of the
               total response observed with the OLP pool. Responses against each of the three individual
               peptides were subsequently assessed in fresh spleen samples from HAdV5–MVA PvDBP_RII
               immunized mice using intracellular cytokine staining (ICS) and flow cytometric analysis.
               These results indicate that each of the three peptides re-stimulated CD4
               <sup>+</sup> T cells (Figure 
               <span ref-type="fig" rid="F3">3</span>E and Table 
               <span ref-type="table" rid="T1">
                  <a href="#T1">1</a>
               </span>) with no responses detected above background for CD8
               <sup>+</sup> T cells (data not shown), in agreement with the earlier data that suggested a paucity
               of detectable CD8
               <sup>+</sup> T cells responses against this antigen in BALB/c mice.
            </p>
            <div id="T1">
               <span class="label">Table 1</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>H-2
                        <sup>d</sup> T cell epitopes mapped in PvDBP_RII
                     </b>.
                  </p>
               </caption>
               <table xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <thead>
                     <tr>
                        <th>Peptide number</th>
                        <th>Sequence</th>
                     </tr>
                  </thead>
                  <div tagxxx="tbody">
                     <tr>
                        <td>7</td>
                        <td>VNNTDTNFHRDITFRKLYLK</td>
                     </tr>
                     <tr>
                        <td>8</td>
                        <td>DITFRKLYLKRKLIYDAAVE</td>
                     </tr>
                     <tr>
                        <td>14</td>
                        <td>YSKVVENNLRSIFGTDEKAQ</td>
                     </tr>
                  </div>
               </table>
               <table-wrap-foot xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <i>32 OLP (20mers overlapping by 10 amino acids, except the final peptide 32 which is
                        an 18mer) were used to map T cell epitopes in BALB/c mice following HAdV5-MVA-PvDBP_RII
                        immunization. Responses against the three peptides in the table were consistently
                        observed by ex vivo IFN-γ ELISpot – results from a representative mouse are shown
                        in Figure 
                        <span ref-type="fig" rid="F3">3</span>D. All three peptides were tested by ICS, and IFN-γ responses were observed from CD4
                        <sup>+</sup> T cells following flow cytometry (Figure 
                        <span ref-type="fig" rid="F3">3</span>E)
                     </i>.
                  </p>
               </table-wrap-foot>
            </div>
         </div>
         <div id="S3-5">
            <h3>Vaccine-induced antibodies inhibit the PvDBP_RII-DARC interaction</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The rationale behind a PvDBP_RII-based vaccine relies on the induction of high-titer
               antibodies that inhibit RBC invasion by preventing the interaction between PvDBP and
               its natural ligand, the Fy antigen/DARC. In the absence of an easily available and
               standardized 
               <i>P. vivax</i> assay of growth inhibition activity to assess anti-merozoite antibody function 
               <i>in vitro</i>, a variety of 
               <i>in vitro</i> receptor–ligand binding inhibition assays have been developed (
               <span ref-type="bibr" rid="B47">
                  <sup>
                     <a href="#B47">47</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B57">
                  <sup>
                     <a href="#B57">57</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B58">
                  <sup>
                     <a href="#B58">58</a>
                  </sup>
               </span>). Here, we used a version of this assay to assess the ability of vaccine-induced
               antibodies to inhibit binding of rDBP to the recombinant N-terminus of DARC (
               <span ref-type="bibr" rid="B47">
                  <sup>
                     <a href="#B47">47</a>
                  </sup>
               </span>). Serum samples from mice immunized with the AM, PPP, and AP regimes described above
               (in Figure 
               <span ref-type="fig" rid="F1">1</span>C) were assayed 2 weeks after the final immunization at day 70 (D70). Sera obtained
               from mice at day 55 (D55) after a priming immunization with HAdV5-PvDBP_RII (i.e.,
               prior to a MVA or protein-in-adjuvant vaccine boost) were also tested. The binding
               inhibition of sera was tested at three different dilutions: 1:1000, 1:2000, and 1:4000
               (Figures 
               <span ref-type="fig" rid="F4">4A–C</span>).
            </p>
            <div tagxxx="fig">
               <span class="label">Figure 4</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>Inhibition of PvDBP_RII binding to its receptor by vaccine-induced antibodies</b>. BALB/c mice (
                     <i>n</i> = 4–5/group) were immunized with the AM, AP, and PPP regimes as described in Figure
                     
                     <span ref-type="fig" rid="F1">1</span>C. Binding inhibition assays were carried out as described in Section “Materials and
                     Methods” using serum from the stated time-points at dilutions of 1:1000, 1:2000, and
                     1:4000. Each sample was run in duplicate or triplicate and the mean% binding inhibition
                     calculated. The mean and SD of the% binding inhibition for the 
                     <b>(A)</b> AM, 
                     <b>(B)</b> PPP, and 
                     <b>(C)</b> AP groups are shown. The controls (
                     <i>n</i> = 3) were high-titer mouse anti-PvDBP_RII serum samples. 
                     <b>(D)</b> Median and individual data points are shown for the 1:4000 serum dilution reported
                     in 
                     <b>(A–C)</b>. Data for day 55 (D55) after HAdV5 are also included. *
                     <i>P</i> &lt; 0.05 and **
                     <i>P</i> &lt; 0.01, see Results for statistical tests. 
                     <b>(E)</b> Relationship between% binding inhibition and log
                     <div tagxxx="sub">10</div> anti-PvDBP_RII IgG titer assessed by endpoint ELISA. Individual data points and non-linear
                     regression curve are shown (
                     <i>n</i> = 87).
                  </p>
               </caption>
               <div tagxxx="graphic"></div>
            </div>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">High levels of binding inhibition, &gt;90%, were achieved with sera from mice immunized
               with the AM regime when tested at 1:1000, and this effect was reduced following dilution
               of the serum (Figure 
               <span ref-type="fig" rid="F4">4</span>A). Inhibition of binding was significantly greater when compared to that after a
               single HAdV5 immunization, in agreement with the increase in IgG titers following
               the MVA boost (Figure 
               <span ref-type="fig" rid="F1">1</span>A). Binding inhibition observed in the AM group was largely comparable to that achieved
               by PPP immunization when using the Montanide
               <sup>®</sup>ISA720 adjuvant. Encouragingly, PPP immunization with the Abisco
               <sup>®</sup>100 adjuvant, or AP immunization using either adjuvant, showed similar high-level
               binding inhibition at 1:1000 serum dilution, which was better maintained at 1:4000
               dilutions.
            </p>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Comparison across all regimes at the 1:4000 serum dilution confirmed low levels of
               binding inhibition (median 14.4%) in mice 55 days after HAdV5-PvDBP_RII immunization
               (Figure 
               <span ref-type="fig" rid="F4">4</span>D). Following a boost with MVA-PvDBP_RII (GFP), binding inhibition titers were significantly
               increased (median 62.7%) (
               <i>P</i> = 0.003, Mann–Whitney test). In comparison to the PPP and AP regimes, titers achieved
               by the AM viral vectors were not significantly different to Montanide
               <sup>®</sup>ISA720 immunized mice (median 65.0% for PPP and 78.0% for AP). However, PPP and AP
               immunization using Abisco
               <sup>®</sup>100 showed a significant improvement over the AM regime (medians of 88.0 and 86.0%,
               respectively) (
               <i>P</i> &lt; 0.05, Kruskal–Wallis test). There was also a strong sigmoidal relationship between
               binding inhibition and antigen-specific IgG titer, as measured by ELISA, across all
               tested samples and dilutions (Figure 
               <span ref-type="fig" rid="F4">4</span>E), similar to other 
               <i>in vitro</i> antibody assays measuring the functional activity of anti-merozoite antibodies (
               <span ref-type="bibr" rid="B55">
                  <sup>
                     <a href="#B55">55</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B59">
                  <sup>
                     <a href="#B59">59</a>
                  </sup>
               </span>). Overall, these data indicated that the highest titers of binding inhibitory antibodies
               could be achieved in mice using an AP immunization regime or a PPP regime when formulating
               the protein vaccine in Abisco
               <sup>®</sup>100.
            </p>
         </div>
         <div id="S3-6">
            <h3>Recognition of native parasite antigen by vaccine-induced antibodies</h3>
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The 
               <i>in vitro</i> binding inhibition assay utilizes rDBP, and does not confirm that vaccine-induced
               antibodies are capable of recognition of native antigen within the 
               <i>P. vivax</i> parasite. In order to assess this, indirect IFAs were performed using slides prepared
               from the blood of 
               <i>P. vivax</i> infected Thai patients. Slides were probed with serum taken 2 weeks after the final
               vaccination from mice immunized with the ChAd63-PvDBP_RII and MVA-PvDBP_RII (ML) vectors
               (AM regime) outlined above in Figure 
               <span ref-type="fig" rid="F1">1</span>B. All of the sera tested from PvDBP_RII immunized mice were positive by IFA with
               a punctate staining pattern, suggesting binding of antibody to PvDBP antigen within
               the micronemes of daughter merozoites (Figure 
               <span ref-type="fig" rid="F5">5</span>A). We also immunized rabbits with the HAdV5 and MVA vectors expressing PvDBP_RII.
               These rabbit sera recognized PvDBP_RII antigen by ELISA, with responses after the
               priming immunization showing a different kinetic to mice (Figure 
               <span ref-type="fig" rid="F5">5</span>B), but similar to that seen in rabbits in previous studies with the AM regime (
               <span ref-type="bibr" rid="B45">
                  <sup>
                     <a href="#B45">45</a>
                  </sup>
               </span>, 
               <span ref-type="bibr" rid="B49">
                  <sup>
                     <a href="#B49">49</a>
                  </sup>
               </span>). Serum from these rabbits, but not from vector immunized controls, also recognized
               
               <i>P. vivax</i> schizonts with a punctate staining pattern (Figure 
               <span ref-type="fig" rid="F5">5</span>C).
            </p>
            <div tagxxx="fig">
               <span class="label">Figure 5</span>
               <caption xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
                  <p>
                     <b>Indirect IFA using serum from adenovirus-MVA PvDBP_RII immunized mice and rabbits</b>. 
                     <b>(A)</b> Indirect IFA using sera from PvDBP_RII and OVA control immunized mice (green) and
                     microscope slides containing fixed 
                     <i>P. vivax-</i>infected cells obtained from patients in Thailand. Representative images are shown
                     for both sets of sera. Nuclei were stained with DAPI. The merge plus bright field
                     are also shown. 
                     <b>(B)</b> ZiKa rabbits (
                     <i>n</i> = 4) were immunized with HAdV5-PvDBP_RII on day 0 and MVA-PvDBP_RII on day 56. Serum
                     was harvested before immunization (day 0) and 28, 56, and 70 days post-adenovirus
                     administration. Serum IgG titers were determined by endpoint ELISA. Individual responses
                     are shown and the solid line indicates the mean. The dotted line indicates the cut-off
                     for a positive response – samples tested at 1:100 dilution that did not show an OD
                     <div tagxxx="sub">405</div> nm reading above negative control sera are plotted below this line. Rabbits immunized
                     with the same vectors encoding OVA showed no detectable responses in the same ELISA
                     assay (not shown). 
                     <b>(C)</b> Indirect IFA as in 
                     <b>(A)</b> using sera from the PvDBP_RII and OVA immunized rabbits (green). Two representative
                     images are shown for both sets of sera.
                  </p>
               </caption>
               <div tagxxx="graphic"></div>
            </div>
         </div>
      </div>
      <div id="S4">
         <h2>Discussion</h2>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">It is almost 40 years since the first report that identified the Duffy blood group
            antigen as a critical determinant of susceptibility to 
            <i>P. vivax</i> malaria (
            <span ref-type="bibr" rid="B15">
               <sup>
                  <a href="#B15">15</a>
               </sup>
            </span>). However, despite great strides in our understanding about the nature of the interaction
            between the PvDBP and its receptor, it has proved challenging to translate vaccine
            candidates based on this paradigm into early phase proof-of-concept clinical testing.
            As for many malaria vaccine candidates, this can be due to difficulties with scale-up
            and manufacture of clinical-grade protein antigen, access to effective adjuvants or
            delivery formulations suitable for human use, as well as finite resources (
            <span ref-type="bibr" rid="B2">
               <sup>
                  <a href="#B2">2</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B27">
               <sup>
                  <a href="#B27">27</a>
               </sup>
            </span>). More recently, advances in subunit vaccine delivery platforms have made it relatively
            easier to raise strong immune responses against target antigens of interest in humans.
            One leading approach has seen the development of recombinant viral vectored technologies
            that allow for 
            <i>in situ</i> expression of the encoded antigen from virally infected cells, leading to the concomitant
            induction of strong cellular and humoral immunity (
            <span ref-type="bibr" rid="B28">
               <sup>
                  <a href="#B28">28</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B51">
               <sup>
                  <a href="#B51">51</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B54">
               <sup>
                  <a href="#B54">54</a>
               </sup>
            </span>). Notably, recombinant adenovirus and poxvirus vectors are now in clinical trials
            ranging from Phase I–III, as vaccine candidates against numerous pathogens including
            
            <i>P. falciparum</i> malaria (
            <span ref-type="bibr" rid="B33">
               <sup>
                  <a href="#B33">33</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B60">
               <sup>
                  <a href="#B60">60</a>
               </sup>
            </span>), HIV-1 (
            <span ref-type="bibr" rid="B61">
               <sup>
                  <a href="#B61">61</a>
               </sup>
            </span>), hepatitis C virus (
            <span ref-type="bibr" rid="B62">
               <sup>
                  <a href="#B62">62</a>
               </sup>
            </span>), 
            <i>Mycobacterium tuberculosis</i> (
            <span ref-type="bibr" rid="B63">
               <sup>
                  <a href="#B63">63</a>
               </sup>
            </span>), influenza virus (
            <span ref-type="bibr" rid="B64">
               <sup>
                  <a href="#B64">64</a>
               </sup>
            </span>), and Ebola (
            <span ref-type="bibr" rid="B34">
               <sup>
                  <a href="#B34">34</a>
               </sup>
            </span>). In this study, viral vectored vaccines, based on both human and chimpanzee adenovirus
            serotypes as well as the poxvirus MVA, were generated and then assessed for their
            ability to raise cellular and humoral immune responses against the blood-stage 
            <i>P. vivax</i> antigen PvDBP_RII in mice and rabbits. Moreover, immune responses elicited by viral
            vectored vaccines encoding PvDBP_RII were compared with responses elicited by immunization
            with rDBP formulated with strong experimental adjuvants that have been used in human
            clinical trials (
            <span ref-type="bibr" rid="B65">
               <sup>
                  <a href="#B65">65</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B66">
               <sup>
                  <a href="#B66">66</a>
               </sup>
            </span>).
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">These studies confirmed that PvDBP_RII is immunogenic and elicits strong antibody
            responses when delivered either by adenoviral and MVA vectors or as recombinant protein
            formulated with adjuvant. Anti-PvDBP_RII-specific IgG antibody responses were induced
            by viral vectored vaccines, and these followed a similar kinetic to that previously
            observed in mice and rabbits in the context of a standard heterologous prime-boost
            (AM) regime with other candidate antigens (
            <span ref-type="bibr" rid="B29">
               <sup>
                  <a href="#B29">29</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B36">
               <sup>
                  <a href="#B36">36</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B45">
               <sup>
                  <a href="#B45">45</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B49">
               <sup>
                  <a href="#B49">49</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B50">
               <sup>
                  <a href="#B50">50</a>
               </sup>
            </span>). Consistent with studies using other malaria transgenes (
            <span ref-type="bibr" rid="B45">
               <sup>
                  <a href="#B45">45</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B49">
               <sup>
                  <a href="#B49">49</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B50">
               <sup>
                  <a href="#B50">50</a>
               </sup>
            </span>), there was no significant difference between IgG titers 2 weeks after a priming
            immunization with either HAdV5 or ChAd63, although there was a trend toward weaker
            antibody titers with ChAd63. Following a boost with recombinant MVA, and consistent
            with numerous other studies (
            <span ref-type="bibr" rid="B45">
               <sup>
                  <a href="#B45">45</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B49">
               <sup>
                  <a href="#B49">49</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B67">
               <sup>
                  <a href="#B67">67</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B68">
               <sup>
                  <a href="#B68">68</a>
               </sup>
            </span>), anti-PvDBP_RII titers and IFN-γ T cell responses were comparable irrespective of
            priming adenovirus vector, or use of a GFP marker gene in the recombinant MVA. In
            recent years, ChAd63 and markerless MVA vectors encoding target antigens from 
            <i>P. falciparum</i> have been routinely progressed to Phase I/II clinical trials (
            <span ref-type="bibr" rid="B44">
               <sup>
                  <a href="#B44">44</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B53">
               <sup>
                  <a href="#B53">53</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B69">
               <sup>
                  <a href="#B69">69</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B70">
               <sup>
                  <a href="#B70">70</a>
               </sup>
            </span>), and the data here suggest the vectors for PvDBP_RII are equally suitable for clinical
            development.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Protection against blood-stage merozoites requires high concentration of functional
            antibody, capable of inhibiting the rapid RBC invasion process (
            <span ref-type="bibr" rid="B32">
               <sup>
                  <a href="#B32">32</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B71">
               <sup>
                  <a href="#B71">71</a>
               </sup>
            </span>). More recently, “mixed modality” adenoviral prime – protein-in-adjuvant boost regimes
            have been developed, and in a recent Phase Ia clinical trial with PfAMA1 antigen,
            were shown to induce higher antigen-specific IgG responses than the standard AM regime
            (
            <span ref-type="bibr" rid="B55">
               <sup>
                  <a href="#B55">55</a>
               </sup>
            </span>). Given the availability of a protein PvDBP_RII vaccine that is also being progressed
            to clinical development (
            <span ref-type="bibr" rid="B72">
               <sup>
                  <a href="#B72">72</a>
               </sup>
            </span>), we also explored the utility of the AP mixed-modality approach with this antigen
            and two “strong” adjuvants that have been in clinical testing (
            <span ref-type="bibr" rid="B65">
               <sup>
                  <a href="#B65">65</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B66">
               <sup>
                  <a href="#B66">66</a>
               </sup>
            </span>). At the doses tested, the AP regime, using both Montanide
            <sup>®</sup>ISA720 and the Abisco
            <sup>®</sup>100 adjuvants, significantly outperformed the AM regime. In comparison to protein-only
            regimes, the AP regime performed comparably to two protein immunizations (PP) with
            Abisco
            <sup>®</sup>100, but tended to improve upon Montanide
            <sup>®</sup>ISA720. Following three protein immunizations (PPP), all regimes performed comparably
            in terms of the total anti-PvDBP_RII IgG response. These regimes also elicited comparable
            levels of IFN-γ T cell responses as measured by ELISpot assay, and in the case of
            BALB/c mice, these appeared largely composed of a CD4
            <sup>+</sup> T cell response directed against one dominant, and at least two sub-dominant, epitopes.
            Natural exposure to 
            <i>P. vivax</i> (
            <span ref-type="bibr" rid="B73">
               <sup>
                  <a href="#B73">73</a>
               </sup>
            </span>), as well as immunization of rhesus macaques with PvDBP_RII protein in Montanide
            <sup>®</sup>ISA720 (
            <span ref-type="bibr" rid="B24">
               <sup>
                  <a href="#B24">24</a>
               </sup>
            </span>), also elicits antigen-specific T cell responses detectable by ELISpot. Their role
            in providing help to B cell responses and/or contribution to acquired immunity remains
            to be better defined.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Consistent with previous reports (
            <span ref-type="bibr" rid="B35">
               <sup>
                  <a href="#B35">35</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B36">
               <sup>
                  <a href="#B36">36</a>
               </sup>
            </span>), adenoviral priming also skewed the antibody response toward the Th1-type IgG2a
            cytophilic isotype, especially in the case of Montanide
            <sup>®</sup>ISA720. The potential role of the equivalent human isotypes IgG1 and IgG3 in natural
            immunity against 
            <i>P. vivax</i> remains unclear, although these subclasses tend to dominate in the natural response
            to merozoite antigens for both 
            <i>P. vivax</i> and 
            <i>P. falciparum</i> (
            <span ref-type="bibr" rid="B74">
               <sup>
                  <a href="#B74">74</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B75">
               <sup>
                  <a href="#B75">75</a>
               </sup>
            </span>) and likely mediate effector functions via their Fc including interactions with immune
            cells (
            <span ref-type="bibr" rid="B76">
               <sup>
                  <a href="#B76">76</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B78">
               <sup>
                  <a href="#B78">78</a>
               </sup>
            </span>) and complement (
            <span ref-type="bibr" rid="B79">
               <sup>
                  <a href="#B79">79</a>
               </sup>
            </span>). The ability to tailor the quality of the antibody response by using different vaccination
            regimes in humans may allow for this question to be better addressed in the future.
            In a similar vein, the ability of different protein vaccine adjuvants to affect the
            “quality” or fine-specificity of the vaccine-induced IgG has been reported in some
            cases (
            <span ref-type="bibr" rid="B80">
               <sup>
                  <a href="#B80">80</a>
               </sup>
            </span>), but not others (
            <span ref-type="bibr" rid="B81">
               <sup>
                  <a href="#B81">81</a>
               </sup>
            </span>), and will warrant further investigation in the context of clinical trials.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The ability of vaccine-induced antibodies to block binding of PvDBP_RII protein to
            its receptor DARC was assessed here using an 
            <i>in vitro</i> ELISA-based binding inhibition assay against the vaccine homologous 
            <i>Sal</i>I allele. The highest levels of binding inhibition were achieved with sera from mice
            immunized using the AP and PPP regimes containing Abisco
            <sup>®</sup>100 at a dilution of 1:4000, with comparable but slightly lower inhibition seen at
            the same dilution when using sera from mice immunized with the AM regime or protein
            in Montanide
            <sup>®</sup>ISA720. These levels were comparable, if not better, than those previously reported
            in similar mouse studies (
            <span ref-type="bibr" rid="B42">
               <sup>
                  <a href="#B42">42</a>
               </sup>
            </span>). Notably, binding inhibition also correlated with IgG titers, as previously reported
            for this assay using sera from immunized rhesus macaques (
            <span ref-type="bibr" rid="B24">
               <sup>
                  <a href="#B24">24</a>
               </sup>
            </span>).
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The antibodies induced here in mice and rabbits by the AM regime were also capable
            of recognizing native 
            <i>P. vivax</i> parasite antigen as assessed by IFA using freshly isolated parasites from Thai patients,
            consistent with other studies using viral vectors to deliver leading 
            <i>P. falciparum</i> antigens in rabbits and humans (
            <span ref-type="bibr" rid="B31">
               <sup>
                  <a href="#B31">31</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B44">
               <sup>
                  <a href="#B44">44</a>
               </sup>
            </span>). It is encouraging that these antibodies can recognize native parasite isolates.
            Studies of naturally acquired immunity following 
            <i>P. vivax</i> exposure have reported the induction of strain-specific immunity (
            <span ref-type="bibr" rid="B82">
               <sup>
                  <a href="#B82">82</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B83">
               <sup>
                  <a href="#B83">83</a>
               </sup>
            </span>), and numerous sequence polymorphisms have been found within the PvDBP_RII antigen
            with the majority localized to subdomain 2 (SD2) (
            <span ref-type="bibr" rid="B84">
               <sup>
                  <a href="#B84">84</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B85">
               <sup>
                  <a href="#B85">85</a>
               </sup>
            </span>). Other studies have suggested that the more highly conserved SD3 is also important
            for PvDBP_RII engagement with DARC and can elicit strain-transcending blocking inhibitory
            antibodies (
            <span ref-type="bibr" rid="B86">
               <sup>
                  <a href="#B86">86</a>
               </sup>
            </span>). Indeed, the development of naturally acquired cross-reactive anti-PvDBP_RII antibodies
            that recognize and block binding of diverse PvDBP_RII domains from 
            <i>P. vivax</i> field isolates have been reported albeit at low frequency (
            <span ref-type="bibr" rid="B26">
               <sup>
                  <a href="#B26">26</a>
               </sup>
            </span>). This may be due to the limited exposure time of the PvDBP_RII micronemal ligand
            prior to binding the DARC receptor.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In contrast to epidemiological data, preclinical immunogenicity studies with the 
            <i>Sal</i>I allele of PvDBP_RII have shown that this immunogen is capable of eliciting high-titer,
            cross-reactive binding-inhibitory antibodies in the ELISA-based assay (
            <span ref-type="bibr" rid="B80">
               <sup>
                  <a href="#B80">80</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B86">
               <sup>
                  <a href="#B86">86</a>
               </sup>
            </span>) and inhibitory capacity using an 
            <i>ex vivo</i> invasion assay (
            <span ref-type="bibr" rid="B87">
               <sup>
                  <a href="#B87">87</a>
               </sup>
            </span>). These data suggest that PvDBP_RII vaccination using either viral vectors or recombinant
            protein formulated with adjuvant could elicit antibodies that quantitatively and qualitatively
            differ from those induced by natural exposure. Whether this translates into the development
            of potent immune responses in humans that cross-react with diverse variants, and provide
            protection against 
            <i>P. vivax</i> blood-stage infections, will be important future questions for clinical trials with
            first-generation vaccines based on PvDBP_RII.
         </p>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Overall, these data confirm the immunogenicity of clinically relevant viral vectors
            in small animal models. The ChAd63 and MVA vectors encoding PvDBP_RII (
            <i>Sal</i>I) have since progressed to Phase Ia clinical testing in healthy adults in Oxford,
            UK (Clinicaltrials.gov NCT01816113). Given the on-going development of a PvDBP_RII
            protein-based vaccine toward clinical manufacture (
            <span ref-type="bibr" rid="B72">
               <sup>
                  <a href="#B72">72</a>
               </sup>
            </span>), it will also be possible to test mixed-modality regimes in Phase Ia trials in due
            course, as recently performed for the PfAMA1 antigen using ChAd63, MVA, and protein-in-adjuvant
            (
            <span ref-type="bibr" rid="B55">
               <sup>
                  <a href="#B55">55</a>
               </sup>
            </span>). The clinical data with ChAd63 and MVA will provide the first opportunity to assess
            the safety and immunogenicity of the PvDBP_RII antigen in humans, and enable detailed
            insight into the human vaccine-induced antibody response against this leading target
            antigen.
         </p>
      </div>
      <div id="S5">
         <h2>Author Contributions</h2>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conceived, designed, and performed the experiments: SC, RS, DL, SE, JC, AG, JJ, AD,
            RS, CC, SD. Analyzed the data: SC, RS, CC, SD. Contributed reagents/materials/analysis
            tools: FN, LR, BR, CC. Wrote the paper: SC, SD.
         </p>
      </div>
      <div id="S6">
         <h2>Conflict of Interest Statement</h2>
         <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Simone C. de Cassan, Anna L. Goodman, Alexander D. Douglas, and Simon J. Draper are
            named inventors on patent applications covering malaria vectored vaccines and immunization
            regimes. Chetan E. Chitnis is a named inventor on a patent covering PvDBP_RII. The
            remaining authors have no conflict of interest to declare.
         </p>
      </div>
      <div tagxxx="back">
         <div tagxxx="ack">
            <p xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">We thank S. Biswas, J. Illingworth, A. Williams, R. Brown, D. Alanine, D. Worth, A.
               Hill, and J. Furze (Jenner Institute, University of Oxford) for assistance, as well
               as the Jenner Institute Vector Core Facility, Flow Cytometry Core Facility, and Adjuvant
               Bank. We also thank Alfredo Nicosia (Okairòs, Italy) for provision of the ChAd63 vector.
               
               <i>Funding</i>: SdC was supported by a Ph.D. studentship from the EMVDA (European Malaria Vaccine
               Development Association, a European Commission (EC) FP6-funded consortium [LSHP-CT-2007-037506]).
               AG was funded by a MRC Clinical Training Fellowship [Grant number G0600424]. DL was
               supported by the Rhodes Trust. This work was supported in part by the Wellcome Trust
               [084113/Z/07/Z]; the UK Medical Research Council (MRC) [G1100086]; and by the European
               Community’s Seventh Framework Program (FP7/2007-2013) under grant agreement No. 242095
               – EVIMalaR. AD held a Wellcome Trust Research Training Fellowship [089455/2/09/Z].
               BR received funding from the Singapore National Medical Research Council (NMRC/CBRG/0047/2013).
               LR was supported by funding from the Singapore Immunology Network (SIgN) and the Horizontal
               Program on Infectious Diseases under the Agency for Science, Technology and Research
               (A*STAR, Singapore). SMRU is sponsored by The Wellcome Trust of Great Britain, as
               part of the Oxford Tropical Medicine Research Program of Wellcome Trust-Mahidol University.
               JC is supported by a Singapore International Graduate Award (SINGA) and hosted by
               the Yong Loo Lin School of Medicine, National University of Singapore (Singapore).
               Work in the laboratory of CC is supported by the Malaria Vaccine Initiative (MVI),
               PATH, and Department of Biotechnology (DBT), Government of India (GoI). CC was a recipient
               of the TATA Innovation Fellowship of DBT, GoI. SD is a Jenner Investigator, Lister
               Institute Research Prize Fellow, and a UK MRC Career Development Fellow [G1000527;
               this Fellowship is jointly funded by the UK MRC and the UK Department for International
               Development (DFID) under the MRC/DFID Concordat agreement].
            </p>
         </div>
         <div tag="ref-list">
            <ul>
               <div tagxxx="title">References</div>
               <li tag="ref">
                  <a name="B1"></a>
                  <span class="label">1</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Hill</span>
                           <span tagx="given-names">AV</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Vaccines against malaria</span>. 
                     <span tagx="source">Philos Trans R Soc Lond B Biol Sci</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">366</span>:
                     <span tagx="fpage">2806</span>–
                     <span tagx="lpage">14</span>.
                     <span class="pub-id'">[10.1098/rstb.2011.0091]</span>
                     <span class="pub-id'">[21893544]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B2"></a>
                  <span class="label">2</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Galinski</span>
                           <span tagx="given-names">MR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Barnwell</span>
                           <span tagx="given-names">JW</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">
                        <i>Plasmodium vivax</i>: who cares?
                     </span>
                     <span tagx="source">Malar J</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">7</span>(
                     <div tagxxx="issue">Suppl 1</div>):
                     <span tagx="fpage">S9</span>.
                     <span class="pub-id'">[10.1186/1475-2875-7-S1-S9]</span>
                     <span class="pub-id'">[19091043]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B3"></a>
                  <span class="label">3</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Gething</span>
                           <span tagx="given-names">PW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elyazar</span>
                           <span tagx="given-names">IR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moyes</span>
                           <span tagx="given-names">CL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Smith</span>
                           <span tagx="given-names">DL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Battle</span>
                           <span tagx="given-names">KE</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Guerra</span>
                           <span tagx="given-names">CA</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A long neglected world malaria map: 
                        <i>Plasmodium vivax</i> endemicity in 2010
                     </span>. 
                     <span tagx="source">PLoS Negl Trop Dis</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">e1814</span>.
                     <span class="pub-id'">[10.1371/journal.pntd.0001814]</span>
                     <span class="pub-id'">[22970336]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B4"></a>
                  <span class="label">4</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Baird</span>
                           <span tagx="given-names">JK</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Evidence and implications of mortality associated with acute 
                        <i>Plasmodium vivax</i> malaria
                     </span>. 
                     <span tagx="source">Clin Microbiol Rev</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">26</span>:
                     <span tagx="fpage">36</span>–
                     <span tagx="lpage">57</span>.
                     <span class="pub-id'">[10.1128/CMR.00074-12]</span>
                     <span class="pub-id'">[23297258]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B5"></a>
                  <span class="label">5</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Moorthy</span>
                           <span tagx="given-names">VS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Newman</span>
                           <span tagx="given-names">RD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Okwo-Bele</span>
                           <span tagx="given-names">JM</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Malaria vaccine technology roadmap</span>. 
                     <span tagx="source">Lancet</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">382</span>:
                     <span tagx="fpage">1700</span>–
                     <span tagx="lpage">1</span>.
                     <span class="pub-id'">[10.1016/S0140-6736(13)62238-2]</span>
                     <span class="pub-id'">[24239252]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B6"></a>
                  <span class="label">6</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Malkin</span>
                           <span tagx="given-names">EM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Durbin</span>
                           <span tagx="given-names">AP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Diemert</span>
                           <span tagx="given-names">DJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sattabongkot</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wu</span>
                           <span tagx="given-names">Y</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Miura</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for 
                        <i>Plasmodium vivax</i> malaria
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2005</span>) 
                     <span tagx="volume">23</span>:
                     <span tagx="fpage">3131</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2004.12.019]</span>
                     <span class="pub-id'">[15837212]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B7"></a>
                  <span class="label">7</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Wu</span>
                           <span tagx="given-names">Y</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ellis</span>
                           <span tagx="given-names">RD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shaffer</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Fontes</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Malkin</span>
                           <span tagx="given-names">EM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mahanty</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25
                        formulated with montanide ISA 51
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">3</span>:
                     <span tagx="fpage">e2636</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0002636]</span>
                     <span class="pub-id'">[18612426]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B8"></a>
                  <span class="label">8</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Herrera</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Fernandez</span>
                           <span tagx="given-names">OL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Vera</span>
                           <span tagx="given-names">O</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Cardenas</span>
                           <span tagx="given-names">W</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ramirez</span>
                           <span tagx="given-names">O</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Palacios</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Phase I safety and immunogenicity trial of 
                        <i>Plasmodium vivax</i> CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide
                        ISA 51
                     </span>. 
                     <span tagx="source">Am J Trop Med Hyg</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">84</span>:
                     <span tagx="fpage">12</span>–
                     <span tagx="lpage">20</span>.
                     <span class="pub-id'">[10.4269/ajtmh.2011.09-0516]</span>
                     <span class="pub-id'">[21292873]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B9"></a>
                  <span class="label">9</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Bennett</span>
                           <span tagx="given-names">JW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Pybus</span>
                           <span tagx="given-names">BS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Yadava</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Tosh</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sousa</span>
                           <span tagx="given-names">JC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mccarthy</span>
                           <span tagx="given-names">WF</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Primaquine failure and cytochrome P-450 2D6 in 
                        <i>Plasmodium vivax</i> malaria
                     </span>. 
                     <span tagx="source">N Engl J Med</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">369</span>:
                     <span tagx="fpage">1381</span>–
                     <span tagx="lpage">2</span>.
                     <span class="pub-id'">[10.1056/NEJMc1301936]</span>
                     <span class="pub-id'">[24088113]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B10"></a>
                  <span class="label">10</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Blood-stage malaria vaccines – recent progress and future challenges</span>. 
                     <span tagx="source">Ann Trop Med Parasitol</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">104</span>:
                     <span tagx="fpage">189</span>–
                     <span tagx="lpage">211</span>.
                     <span class="pub-id'">[10.1179/136485910X12647085215534]</span>
                     <span class="pub-id'">[20507694]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B11"></a>
                  <span class="label">11</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Arevalo-Herrera</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Herrera</span>
                           <span tagx="given-names">S</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Current status of 
                        <i>Plasmodium vivax</i> vaccine
                     </span>. 
                     <span tagx="source">Hum Vaccin</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">124</span>–
                     <span tagx="lpage">32</span>.
                     <span class="pub-id'">[10.4161/hv.6.1.9931]</span>
                     <span class="pub-id'">[20009526]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B12"></a>
                  <span class="label">12</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Harvey</span>
                           <span tagx="given-names">KL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilson</span>
                           <span tagx="given-names">PR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Crabb</span>
                           <span tagx="given-names">BS</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">A model for the progression of receptor-ligand interactions during erythrocyte invasion
                        by 
                        <i>Plasmodium falciparum</i>
                     </span>. 
                     <span tagx="source">Int J Parasitol</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">42</span>:
                     <span tagx="fpage">567</span>–
                     <span tagx="lpage">73</span>.
                     <span class="pub-id'">[10.1016/j.ijpara.2012.02.011]</span>
                     <span class="pub-id'">[22710063]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B13"></a>
                  <span class="label">13</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Malleret</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Li</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Tan</span>
                           <span tagx="given-names">KS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Suwanarusk</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Claser</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">
                        <i>Plasmodium vivax</i>: restricted tropism and rapid remodeling of CD71-positive reticulocytes
                     </span>. 
                     <span tagx="source">Blood</span> (
                     <span tagx="year">2015</span>) 
                     <span tagx="volume">125</span>:
                     <span tagx="fpage">1314</span>–
                     <span tagx="lpage">24</span>.
                     <span class="pub-id'">[10.1182/blood-2014-08-596015]</span>
                     <span class="pub-id'">[25414440]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B14"></a>
                  <span class="label">14</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sharma</span>
                           <span tagx="given-names">A</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Targeting the 
                        <i>Plasmodium vivax</i> Duffy-binding protein
                     </span>. 
                     <span tagx="source">Trends Parasitol</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">24</span>:
                     <span tagx="fpage">29</span>–
                     <span tagx="lpage">34</span>.
                     <span class="pub-id'">[10.1016/j.pt.2007.10.004]</span>
                     <span class="pub-id'">[18023618]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B15"></a>
                  <span class="label">15</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Miller</span>
                           <span tagx="given-names">LH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mason</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Clyde</span>
                           <span tagx="given-names">DF</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mcginniss</span>
                           <span tagx="given-names">MH</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">The resistance factor to 
                        <i>Plasmodium vivax</i> in blacks. The Duffy-blood-group genotype, FyFy
                     </span>. 
                     <span tagx="source">N Engl J Med</span> (
                     <span tagx="year">1976</span>) 
                     <span tagx="volume">295</span>:
                     <span tagx="fpage">302</span>–
                     <span tagx="lpage">4</span>.
                     <span class="pub-id'">[10.1056/NEJM197608052950602]</span>
                     <span class="pub-id'">[778616]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B16"></a>
                  <span class="label">16</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Herrera</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Solarte</span>
                           <span tagx="given-names">Y</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Jordan-Villegas</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Echavarria</span>
                           <span tagx="given-names">JF</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rocha</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Palacios</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Consistent safety and infectivity in sporozoite challenge model of 
                        <i>Plasmodium vivax</i> in malaria-naive human volunteers
                     </span>. 
                     <span tagx="source">Am J Trop Med Hyg</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">84</span>:
                     <span tagx="fpage">4</span>–
                     <span tagx="lpage">11</span>.
                     <span class="pub-id'">[10.4269/ajtmh.2011.09-0498]</span>
                     <span class="pub-id'">[21292872]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B17"></a>
                  <span class="label">17</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Howes</span>
                           <span tagx="given-names">RE</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Patil</span>
                           <span tagx="given-names">AP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Piel</span>
                           <span tagx="given-names">FB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Nyangiri</span>
                           <span tagx="given-names">OA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kabaria</span>
                           <span tagx="given-names">CW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gething</span>
                           <span tagx="given-names">PW</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">The global distribution of the Duffy blood group</span>. 
                     <span tagx="source">Nat Commun</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">2</span>:
                     <span tagx="fpage">266</span>
                     <span class="pub-id'">[10.1038/ncomms1265]</span>
                     <span class="pub-id'">[21468018]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B18"></a>
                  <span class="label">18</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Menard</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Barnadas</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bouchier</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Henry-Halldin</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gray</span>
                           <span tagx="given-names">LR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ratsimbasoa</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">
                        <i>Plasmodium vivax</i> clinical malaria is commonly observed in Duffy-negative Malagasy people
                     </span>. 
                     <span tagx="source">Proc Natl Acad Sci U S A</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">107</span>:
                     <span tagx="fpage">5967</span>–
                     <span tagx="lpage">71</span>.
                     <span class="pub-id'">[10.1073/pnas.0912496107]</span>
                     <span class="pub-id'">[20231434]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B19"></a>
                  <span class="label">19</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Menard</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chan</span>
                           <span tagx="given-names">ER</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Benedet</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ratsimbasoa</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kim</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chim</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Whole genome sequencing of field isolates reveals a common duplication of the Duffy
                        binding protein gene in Malagasy 
                        <i>Plasmodium vivax</i> strains
                     </span>. 
                     <span tagx="source">PLoS Negl Trop Dis</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">7</span>:
                     <span tagx="fpage">e2489</span>.
                     <span class="pub-id'">[10.1371/journal.pntd.0002489]</span>
                     <span class="pub-id'">[24278487]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B20"></a>
                  <span class="label">20</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Tham</span>
                           <span tagx="given-names">WH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Healer</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Cowman</span>
                           <span tagx="given-names">AF</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Erythrocyte and reticulocyte binding-like ­proteins of 
                        <i>Plasmodium falciparum</i>
                     </span>. 
                     <span tagx="source">Trends Parasitol</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">28</span>:
                     <span tagx="fpage">23</span>–
                     <span tagx="lpage">30</span>.
                     <span class="pub-id'">[10.1016/j.pt.2011.10.002]</span>
                     <span class="pub-id'">[22178537]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B21"></a>
                  <span class="label">21</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Singh</span>
                           <span tagx="given-names">AP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ozwara</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kocken</span>
                           <span tagx="given-names">CH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Puri</span>
                           <span tagx="given-names">SK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Thomas</span>
                           <span tagx="given-names">AW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Targeted deletion of 
                        <i>Plasmodium knowlesi</i> Duffy binding protein confirms its role in junction formation during invasion
                     </span>. 
                     <span tagx="source">Mol Microbiol</span> (
                     <span tagx="year">2005</span>) 
                     <span tagx="volume">55</span>:
                     <span tagx="fpage">1925</span>–
                     <span tagx="lpage">34</span>.
                     <span class="pub-id'">[10.1111/j.1365-2958.2005.04523.x]</span>
                     <span class="pub-id'">[15752210]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B22"></a>
                  <span class="label">22</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Miller</span>
                           <span tagx="given-names">LH</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Identification of the erythrocyte binding domains of 
                        <i>Plasmodium vivax</i> and 
                        <i>Plasmodium knowlesi</i> proteins involved in erythrocyte invasion
                     </span>. 
                     <span tagx="source">J Exp Med</span> (
                     <span tagx="year">1994</span>) 
                     <span tagx="volume">180</span>:
                     <span tagx="fpage">497</span>–
                     <span tagx="lpage">506</span>.
                     <span class="pub-id'">[10.1084/jem.180.2.497]</span>
                     <span class="pub-id'">[8046329]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B23"></a>
                  <span class="label">23</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Yazdani</span>
                           <span tagx="given-names">SS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mukherjee</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Baniwal</span>
                           <span tagx="given-names">SK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Evaluation of immune responses elicited in mice against a recombinant malaria vaccine
                        based on 
                        <i>Plasmodium vivax</i> Duffy binding protein
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2004</span>) 
                     <span tagx="volume">22</span>:
                     <span tagx="fpage">3727</span>–
                     <span tagx="lpage">37</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2004.03.030]</span>
                     <span class="pub-id'">[15315853]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B24"></a>
                  <span class="label">24</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Moreno</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Caro-Aguilar</span>
                           <span tagx="given-names">I</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Yazdani</span>
                           <span tagx="given-names">SS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lapp</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Strobert</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Preclinical assessment of the receptor-binding domain of 
                        <i>Plasmodium vivax</i> Duffy-binding protein as a vaccine candidate in rhesus macaques
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">26</span>:
                     <span tagx="fpage">4338</span>–
                     <span tagx="lpage">44</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2008.06.010]</span>
                     <span class="pub-id'">[18573299]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B25"></a>
                  <span class="label">25</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Singh</span>
                           <span tagx="given-names">AP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Puri</span>
                           <span tagx="given-names">SK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Antibodies raised against receptor-binding domain of 
                        <i>Plasmodium knowlesi</i> Duffy binding protein inhibit erythrocyte invasion
                     </span>. 
                     <span tagx="source">Mol Biochem Parasitol</span> (
                     <span tagx="year">2002</span>) 
                     <span tagx="volume">121</span>:
                     <span tagx="fpage">21</span>–
                     <span tagx="lpage">31</span>.
                     <span class="pub-id'">[10.1016/S0166-6851(02)00017-8]</span>
                     <span class="pub-id'">[11985860]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B26"></a>
                  <span class="label">26</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">King</span>
                           <span tagx="given-names">CL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Michon</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Marcotty</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Stanisic</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Zimmerman</span>
                           <span tagx="given-names">PA</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer
                        protection from blood-stage 
                        <i>Plasmodium vivax</i> infection
                     </span>. 
                     <span tagx="source">Proc Natl Acad Sci U S A</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">105</span>:
                     <span tagx="fpage">8363</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1073/pnas.0800371105]</span>
                     <span class="pub-id'">[18523022]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B27"></a>
                  <span class="label">27</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Coler</span>
                           <span tagx="given-names">RN</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Carter</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Friede</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Reed</span>
                           <span tagx="given-names">SG</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Adjuvants for malaria vaccines</span>. 
                     <span tagx="source">Parasite Immunol</span> (
                     <span tagx="year">2009</span>) 
                     <span tagx="volume">31</span>:
                     <span tagx="fpage">520</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1111/j.1365-3024.2009.01142.x]</span>
                     <span class="pub-id'">[19691556]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B28"></a>
                  <span class="label">28</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">de Cassan</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery
                        platforms for difficult disease targets
                     </span>. 
                     <span tagx="source">Expert Rev Vaccines</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">12</span>:
                     <span tagx="fpage">365</span>–
                     <span tagx="lpage">78</span>.
                     <span class="pub-id'">[10.1586/erv.13.11]</span>
                     <span class="pub-id'">[23560918]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B29"></a>
                  <span class="label">29</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moore</span>
                           <span tagx="given-names">AC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Long</span>
                           <span tagx="given-names">CA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Holder</span>
                           <span tagx="given-names">AA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Effective induction of high-titer antibodies by viral vector vaccines</span>. 
                     <span tagx="source">Nat Med</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">14</span>:
                     <span tagx="fpage">819</span>–
                     <span tagx="lpage">21</span>.
                     <span class="pub-id'">[10.1038/nm.1850]</span>
                     <span class="pub-id'">[18660818]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B30"></a>
                  <span class="label">30</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Spencer</span>
                           <span tagx="given-names">AJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Remarque</span>
                           <span tagx="given-names">EJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Capone</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Naddeo</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by
                        combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">185</span>:
                     <span tagx="fpage">7583</span>–
                     <span tagx="lpage">95</span>.
                     <span class="pub-id'">[10.4049/jimmunol.1001760]</span>
                     <span class="pub-id'">[21098232]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B31"></a>
                  <span class="label">31</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Williams</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Illingworth</span>
                           <span tagx="given-names">JJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kamuyu</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain
                        neutralizing antibody
                     </span>. 
                     <span tagx="source">Nat Commun</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">2</span>:
                     <span tagx="fpage">601</span>.
                     <span class="pub-id'">[10.1038/ncomms1615]</span>
                     <span class="pub-id'">[22186897]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B32"></a>
                  <span class="label">32</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Baldeviano</span>
                           <span tagx="given-names">GC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lucas</span>
                           <span tagx="given-names">CM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lugo-Roman</span>
                           <span tagx="given-names">LA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Crosnier</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bartholdson</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A PfRH5-based vaccine is efficacious against heterologous strain blood-stage 
                        <i>Plasmodium falciparum</i> infection in 
                        <i>Aotus</i> monkeys
                     </span>. 
                     <span tagx="source">Cell Host Microbe</span> (
                     <span tagx="year">2015</span>) 
                     <span tagx="volume">17</span>:
                     <span tagx="fpage">130</span>–
                     <span tagx="lpage">9</span>.
                     <span class="pub-id'">[10.1016/j.chom.2014.11.017]</span>
                     <span class="pub-id'">[25590760]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B33"></a>
                  <span class="label">33</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Sheehy</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">CJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Choudhary</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Halstead</span>
                           <span tagx="given-names">FD</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment
                        of efficacy against mosquito bite challenge in humans
                     </span>. 
                     <span tagx="source">Mol Ther</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">20</span>:
                     <span tagx="fpage">2355</span>–
                     <span tagx="lpage">68</span>.
                     <span class="pub-id'">[10.1038/mt.2012.223]</span>
                     <span class="pub-id'">[23089736]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B34"></a>
                  <span class="label">34</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Rampling</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ewer</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bowyer</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wright</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Imoukhuede</span>
                           <span tagx="given-names">EB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Payne</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A monovalent chimpanzee adenovirus ebola vaccine – preliminary report</span>. 
                     <span tagx="source">N Engl J Med</span> (
                     <span tagx="year">2015</span>).
                     <span class="pub-id'">[10.1056/NEJMoa1411627]</span>
                     <span class="pub-id'">[25629663]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B35"></a>
                  <span class="label">35</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">De Cassan</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dicks</span>
                           <span tagx="given-names">MD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hill</span>
                           <span tagx="given-names">AV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses
                        by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against
                        
                        <i>Plasmodium falciparum</i> MSP1
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">28</span>:
                     <span tagx="fpage">7167</span>–
                     <span tagx="lpage">78</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2010.08.068]</span>
                     <span class="pub-id'">[20937436]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B36"></a>
                  <span class="label">36</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">de Cassan</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Forbes</span>
                           <span tagx="given-names">EK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Milicic</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Singh</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gupta</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">The requirement for potent adjuvants to enhance the immunogenicity and protective
                        efficacy of protein vaccines can be overcome by prior immunization with a recombinant
                        adenovirus
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">187</span>:
                     <span tagx="fpage">2602</span>–
                     <span tagx="lpage">16</span>.
                     <span class="pub-id'">[10.4049/jimmunol.1101004]</span>
                     <span class="pub-id'">[21813775]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B37"></a>
                  <span class="label">37</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Vinner</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Therrien</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wee</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Laursen</span>
                           <span tagx="given-names">I</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hanke</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Corbet</span>
                           <span tagx="given-names">SL</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant
                        adenovirus and recombinant gp120 from human immunodeficiency virus type 1
                     </span>. 
                     <span tagx="source">APMIS</span> (
                     <span tagx="year">2006</span>) 
                     <span tagx="volume">114</span>:
                     <span tagx="fpage">690</span>–
                     <span tagx="lpage">9</span>.
                     <span class="pub-id'">[10.1111/j.1600-0463.2006.apm_395.x]</span>
                     <span class="pub-id'">[17004972]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B38"></a>
                  <span class="label">38</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Stewart</span>
                           <span tagx="given-names">VA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mcgrath</span>
                           <span tagx="given-names">SM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dubois</span>
                           <span tagx="given-names">PM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Pau</span>
                           <span tagx="given-names">MG</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mettens</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shott</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B
                        boosting significantly improves immunogenicity to 
                        <i>Plasmodium falciparum</i> CS compared to that with either malaria vaccine alone
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2007</span>) 
                     <span tagx="volume">75</span>:
                     <span tagx="fpage">2283</span>–
                     <span tagx="lpage">90</span>.
                     <span class="pub-id'">[10.1128/IAI.01879-06]</span>
                     <span class="pub-id'">[17307942]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B39"></a>
                  <span class="label">39</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Dicks</span>
                           <span tagx="given-names">MD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Spencer</span>
                           <span tagx="given-names">AJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Edwards</span>
                           <span tagx="given-names">NJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wadell</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bojang</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems
                        for vector derivation and comparative immunogenicity
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">7</span>:
                     <span tagx="fpage">e40385</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0040385]</span>
                     <span class="pub-id'">[22808149]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B40"></a>
                  <span class="label">40</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Sridhar</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Reyes-Sandoval</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moore</span>
                           <span tagx="given-names">AC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gao</span>
                           <span tagx="given-names">GP</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Single-dose protection against 
                        <i>Plasmodium berghei</i> by a simian adenovirus vector using a human cytomegalovirus promoter containing intron
                        A
                     </span>. 
                     <span tagx="source">J Virol</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">82</span>:
                     <span tagx="fpage">3822</span>–
                     <span tagx="lpage">33</span>.
                     <span class="pub-id'">[10.1128/JVI.02568-07]</span>
                     <span class="pub-id'">[18256155]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B41"></a>
                  <span class="label">41</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Forbes</span>
                           <span tagx="given-names">EK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Williams</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">De Cassan</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bauza</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">The utility of 
                        <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment
                     </span>. 
                     <span tagx="source">Sci Rep</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">3</span>:
                     <span tagx="fpage">1706</span>.
                     <span class="pub-id'">[10.1038/srep01706]</span>
                     <span class="pub-id'">[23609325]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B42"></a>
                  <span class="label">42</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Devi</span>
                           <span tagx="given-names">YS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mukherjee</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Yazdani</span>
                           <span tagx="given-names">SS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mazumdar</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Pandey</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Immunogenicity of 
                        <i>Plasmodium vivax</i> combination subunit vaccine formulated with human compatible adjuvants in mice
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2007</span>) 
                     <span tagx="volume">25</span>:
                     <span tagx="fpage">5166</span>–
                     <span tagx="lpage">74</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2007.04.080]</span>
                     <span class="pub-id'">[17544179]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B43"></a>
                  <span class="label">43</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Miura</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Orcutt</span>
                           <span tagx="given-names">AC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Muratova</span>
                           <span tagx="given-names">OV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Miller</span>
                           <span tagx="given-names">LH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Saul</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Long</span>
                           <span tagx="given-names">CA</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Development and characterization of a standardized ELISA including a reference serum
                        on each plate to detect antibodies induced by experimental malaria vaccines
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">26</span>:
                     <span tagx="fpage">193</span>–
                     <span tagx="lpage">200</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2007.10.064]</span>
                     <span class="pub-id'">[18054414]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B44"></a>
                  <span class="label">44</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Sheehy</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">CJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ewer</span>
                           <span tagx="given-names">KJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Spencer</span>
                           <span tagx="given-names">AJ</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Phase Ia clinical evaluation of the 
                        <i>Plasmodium falciparum</i> blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
                     </span>. 
                     <span tagx="source">Mol Ther</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">19</span>:
                     <span tagx="fpage">2269</span>–
                     <span tagx="lpage">76</span>.
                     <span class="pub-id'">[10.1038/mt.2011.176]</span>
                     <span class="pub-id'">[21862998]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B45"></a>
                  <span class="label">45</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dicks</span>
                           <span tagx="given-names">MD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Long</span>
                           <span tagx="given-names">CA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Remarque</span>
                           <span tagx="given-names">EJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Siani</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Colloca</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines
                        expressing two alleles of 
                        <i>Plasmodium falciparum</i> AMA1
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">e20977</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0020977]</span>
                     <span class="pub-id'">[21698193]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B46"></a>
                  <span class="label">46</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Forbes</span>
                           <span tagx="given-names">EK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hill</span>
                           <span tagx="given-names">AV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms
                        of CD8+ T cell interference
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">187</span>:
                     <span tagx="fpage">3738</span>–
                     <span tagx="lpage">50</span>.
                     <span class="pub-id'">[10.4049/jimmunol.1003783]</span>
                     <span class="pub-id'">[21876036]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B47"></a>
                  <span class="label">47</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rizvi</span>
                           <span tagx="given-names">MM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Development of quantitative receptor-ligand binding assay for use as a tool to estimate
                        immune responses against 
                        <i>Plasmodium vivax</i> Duffy binding protein region II
                     </span>. 
                     <span tagx="source">J Immunoassay Immunochem</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">33</span>:
                     <span tagx="fpage">403</span>–
                     <span tagx="lpage">13</span>.
                     <span class="pub-id'">[10.1080/15321819.2012.659781]</span>
                     <span class="pub-id'">[22963489]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B48"></a>
                  <span class="label">48</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Vicentin</span>
                           <span tagx="given-names">EC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Francoso</span>
                           <span tagx="given-names">KS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rocha</span>
                           <span tagx="given-names">MV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Iourtov</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dos Santos</span>
                           <span tagx="given-names">FL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kubrusly</span>
                           <span tagx="given-names">FS</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Invasion-inhibitory antibodies elicited by immunization with 
                        <i>Plasmodium vivax</i> apical membrane antigen-1 expressed in 
                        <i>Pichia pastoris</i> yeast
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">82</span>:
                     <span tagx="fpage">1296</span>–
                     <span tagx="lpage">307</span>.
                     <span class="pub-id'">[10.1128/IAI.01169-13]</span>
                     <span class="pub-id'">[24379279]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B49"></a>
                  <span class="label">49</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Epp</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moss</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Holder</span>
                           <span tagx="given-names">AA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wilson</span>
                           <span tagx="given-names">JM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gao</span>
                           <span tagx="given-names">GP</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">New candidate vaccines against blood-stage 
                        <i>Plasmodium falciparum</i> malaria: prime-boost immunization regimens incorporating human and simian adenoviral
                        vectors and poxviral vectors expressing an optimized antigen based on merozoite surface
                        protein 1
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">78</span>:
                     <span tagx="fpage">4601</span>–
                     <span tagx="lpage">12</span>.
                     <span class="pub-id'">[10.1128/IAI.00315-10]</span>
                     <span class="pub-id'">[20713623]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B50"></a>
                  <span class="label">50</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Goodman</span>
                           <span tagx="given-names">AL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Blagborough</span>
                           <span tagx="given-names">AM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wu</span>
                           <span tagx="given-names">Y</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hill</span>
                           <span tagx="given-names">AV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sinden</span>
                           <span tagx="given-names">RE</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen
                        induces transmission-blocking activity
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">e29428</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0029428]</span>
                     <span class="pub-id'">[22216279]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B51"></a>
                  <span class="label">51</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Draper</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Heeney</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Viruses as vaccine vectors for infectious diseases and cancer</span>. 
                     <span tagx="source">Nat Rev Microbiol</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">8</span>:
                     <span tagx="fpage">62</span>–
                     <span tagx="lpage">73</span>.
                     <span class="pub-id'">[10.1038/nrmicro2240]</span>
                     <span class="pub-id'">[19966816]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B52"></a>
                  <span class="label">52</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Colloca</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Barnes</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Folgori</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ammendola</span>
                           <span tagx="given-names">V</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Capone</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Cirillo</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Vaccine vectors derived from a large collection of simian adenoviruses induce potent
                        cellular immunity across multiple species
                     </span>. 
                     <span tagx="source">Sci Transl Med</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">4</span>:
                     <span tagx="fpage">115ra112</span>.
                     <span class="pub-id'">[10.1126/scitranslmed.3002925]</span>
                     <span class="pub-id'">[22218691]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B53"></a>
                  <span class="label">53</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Sheehy</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">CJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">O’hara</span>
                           <span tagx="given-names">GA</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Phase Ia clinical evaluation of the safety and immunogenicity of the 
                        <i>Plasmodium falciparum</i> blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">7</span>:
                     <span tagx="fpage">e31208</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0031208]</span>
                     <span class="pub-id'">[22363582]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B54"></a>
                  <span class="label">54</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Capone</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">D’alise</span>
                           <span tagx="given-names">AM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ammendola</span>
                           <span tagx="given-names">V</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Colloca</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Cortese</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Nicosia</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes
                        emerging from clinical trials
                     </span>. 
                     <span tagx="source">Expert Rev Vaccines</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">12</span>:
                     <span tagx="fpage">379</span>–
                     <span tagx="lpage">93</span>.
                     <span class="pub-id'">[10.1586/erv.13.15]</span>
                     <span class="pub-id'">[23560919]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B55"></a>
                  <span class="label">55</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Hodgson</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Choudhary</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Milne</span>
                           <span tagx="given-names">KH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rampling</span>
                           <span tagx="given-names">TW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage
                        malaria antigen AMA1: report on a phase 1a clinical trial
                     </span>. 
                     <span tagx="source">Mol Ther</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">22</span>:
                     <span tagx="fpage">2142</span>–
                     <span tagx="lpage">54</span>.
                     <span class="pub-id'">[10.1038/mt.2014.157]</span>
                     <span class="pub-id'">[25156127]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B56"></a>
                  <span class="label">56</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Crotty</span>
                           <span tagx="given-names">S</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">The 1-1-1 fallacy</span>. 
                     <span tagx="source">Immunol Rev</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">247</span>:
                     <span tagx="fpage">133</span>–
                     <span tagx="lpage">42</span>.
                     <span class="pub-id'">[10.1111/j.1600-065X.2012.01117.x]</span>
                     <span class="pub-id'">[22500837]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B57"></a>
                  <span class="label">57</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Grimberg</span>
                           <span tagx="given-names">BT</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Udomsangpetch</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Xainli</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mchenry</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Panichakul</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sattabongkot</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">
                        <i>Plasmodium vivax</i> invasion of human erythrocytes inhibited by antibodies directed against the Duffy
                        binding protein
                     </span>. 
                     <span tagx="source">PLoS Med</span> (
                     <span tagx="year">2007</span>) 
                     <span tagx="volume">4</span>:
                     <span tagx="fpage">e337</span>.
                     <span class="pub-id'">[10.1371/journal.pmed.0040337]</span>
                     <span class="pub-id'">[18092885]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B58"></a>
                  <span class="label">58</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Ntumngia</span>
                           <span tagx="given-names">FB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Schloegel</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Barnes</span>
                           <span tagx="given-names">SJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mchenry</span>
                           <span tagx="given-names">AM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Singh</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">King</span>
                           <span tagx="given-names">CL</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Conserved and variant epitopes of 
                        <i>Plasmodium vivax</i> Duffy binding protein as targets of inhibitory monoclonal antibodies
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">80</span>:
                     <span tagx="fpage">1203</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1128/IAI.05924-11]</span>
                     <span class="pub-id'">[22215740]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B59"></a>
                  <span class="label">59</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Miura</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Zhou</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Diouf</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moretz</span>
                           <span tagx="given-names">SE</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Fay</span>
                           <span tagx="given-names">MP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Miller</span>
                           <span tagx="given-names">LH</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-­merozoite-surface-protein-1
                        antibody in inhibiting 
                        <i>Plasmodium falciparum</i> growth, as determined by the in vitro growth inhibition assay
                     </span>. 
                     <span tagx="source">Clin Vaccine Immunol</span> (
                     <span tagx="year">2009</span>) 
                     <span tagx="volume">16</span>:
                     <span tagx="fpage">963</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1128/CVI.00042-09]</span>
                     <span class="pub-id'">[19439523]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B60"></a>
                  <span class="label">60</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Ewer</span>
                           <span tagx="given-names">KJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">O’hara</span>
                           <span tagx="given-names">GA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">CJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sheehy</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Reyes-Sandoval</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA
                        immunisation
                     </span>. 
                     <span tagx="source">Nat Commun</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">4</span>:
                     <span tagx="fpage">2836</span>.
                     <span class="pub-id'">[10.1038/ncomms3836]</span>
                     <span class="pub-id'">[24284865]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B61"></a>
                  <span class="label">61</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Borthwick</span>
                           <span tagx="given-names">N</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ahmed</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ondondo</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hayes</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rose</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ebrahimsa</span>
                           <span tagx="given-names">U</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1</span>. 
                     <span tagx="source">Mol Ther</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">22</span>:
                     <span tagx="fpage">464</span>–
                     <span tagx="lpage">75</span>.
                     <span class="pub-id'">[10.1038/mt.2013.248]</span>
                     <span class="pub-id'">[24166483]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B62"></a>
                  <span class="label">62</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Swadling</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Capone</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Antrobus</span>
                           <span tagx="given-names">RD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Brown</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Richardson</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Newell</span>
                           <span tagx="given-names">EW</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes,
                        boosts, and sustains functional HCV-specific T cell memory
                     </span>. 
                     <span tagx="source">Sci Transl Med</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">261ra153</span>.
                     <span class="pub-id'">[10.1126/scitranslmed.3009185]</span>
                     <span class="pub-id'">[25378645]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B63"></a>
                  <span class="label">63</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Ndiaye</span>
                           <span tagx="given-names">BP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Thienemann</span>
                           <span tagx="given-names">F</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ota</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Landry</span>
                           <span tagx="given-names">BS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Camara</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dieye</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A
                        in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
                     </span>. 
                     <span tagx="source">Lancet Respir Med</span> (
                     <span tagx="year">2015</span>) 
                     <span tagx="volume">3</span>:
                     <span tagx="fpage">190</span>–
                     <span tagx="lpage">200</span>.
                     <span class="pub-id'">[10.1016/S2213-2600(15)00037-5]</span>
                     <span class="pub-id'">[25726088]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B64"></a>
                  <span class="label">64</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Antrobus</span>
                           <span tagx="given-names">RD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Coughlan</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Berthoud</span>
                           <span tagx="given-names">TK</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dicks</span>
                           <span tagx="given-names">MD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hill</span>
                           <span tagx="given-names">AV</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lambe</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored
                        vaccine expressing conserved influenza A antigens
                     </span>. 
                     <span tagx="source">Mol Ther</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">22</span>:
                     <span tagx="fpage">668</span>–
                     <span tagx="lpage">74</span>.
                     <span class="pub-id'">[10.1038/mt.2013.284]</span>
                     <span class="pub-id'">[24374965]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B65"></a>
                  <span class="label">65</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Roestenberg</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Remarque</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">De Jonge</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hermsen</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Blythman</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Leroy</span>
                           <span tagx="given-names">O</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Safety and immunogenicity of a recombinant 
                        <i>Plasmodium falciparum</i> AMA1 malaria vaccine adjuvanted with alhydrogel, montanide ISA 720 or AS02
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2008</span>) 
                     <span tagx="volume">3</span>:
                     <span tagx="fpage">e3960</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0003960]</span>
                     <span class="pub-id'">[19093004]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B66"></a>
                  <span class="label">66</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Cox</span>
                           <span tagx="given-names">RJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Pedersen</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Madhun</span>
                           <span tagx="given-names">AS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Svindland</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Saevik</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Breakwell</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase
                        I clinical trial
                     </span>. 
                     <span tagx="source">Vaccine</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">29</span>:
                     <span tagx="fpage">8049</span>–
                     <span tagx="lpage">59</span>.
                     <span class="pub-id'">[10.1016/j.vaccine.2011.08.042]</span>
                     <span class="pub-id'">[21864624]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B67"></a>
                  <span class="label">67</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Reyes-Sandoval</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Berthoud</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Alder</span>
                           <span tagx="given-names">N</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Siani</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gilbert</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Nicosia</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors
                        enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2010</span>) 
                     <span tagx="volume">78</span>:
                     <span tagx="fpage">145</span>–
                     <span tagx="lpage">53</span>.
                     <span class="pub-id'">[10.1128/IAI.00740-09]</span>
                     <span class="pub-id'">[19858306]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B68"></a>
                  <span class="label">68</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Quinn</span>
                           <span tagx="given-names">KM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Da Costa</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Yamamoto</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Berry</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lindsay</span>
                           <span tagx="given-names">RW</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Darrah</span>
                           <span tagx="given-names">PA</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Comparative analysis of the magnitude, quality, phenotype, and protective capacity
                        of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-,
                        and chimpanzee-derived recombinant adenoviral vector immunization
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">190</span>:
                     <span tagx="fpage">2720</span>–
                     <span tagx="lpage">35</span>.
                     <span class="pub-id'">[10.4049/jimmunol.1202861]</span>
                     <span class="pub-id'">[23390298]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B69"></a>
                  <span class="label">69</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">O’Hara</span>
                           <span tagx="given-names">GA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">CJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ewer</span>
                           <span tagx="given-names">KJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Halstead</span>
                           <span tagx="given-names">FD</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine
                        vector
                     </span>. 
                     <span tagx="source">J Infect Dis</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">205</span>:
                     <span tagx="fpage">772</span>–
                     <span tagx="lpage">81</span>.
                     <span class="pub-id'">[10.1093/infdis/jir850]</span>
                     <span class="pub-id'">[22275401]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B70"></a>
                  <span class="label">70</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">de Barra</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hodgson</span>
                           <span tagx="given-names">SH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ewer</span>
                           <span tagx="given-names">KJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bliss</span>
                           <span tagx="given-names">CM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Hennigan</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Collins</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates
                        ChAd63 CS administered alone and with MVA CS
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">9</span>:
                     <span tagx="fpage">e115161</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0115161]</span>
                     <span class="pub-id'">[25522180]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B71"></a>
                  <span class="label">71</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Douglas</span>
                           <span tagx="given-names">AD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Williams</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Knuepfer</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Illingworth</span>
                           <span tagx="given-names">JJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Furze</span>
                           <span tagx="given-names">JM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Crosnier</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Neutralization of 
                        <i>Plasmodium falciparum</i> merozoites by antibodies against PfRH5
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">192</span>:
                     <span tagx="fpage">245</span>–
                     <span tagx="lpage">58</span>.
                     <span class="pub-id'">[10.4049/jimmunol.1302045]</span>
                     <span class="pub-id'">[24293631]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B72"></a>
                  <span class="label">72</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Yazdani</span>
                           <span tagx="given-names">SS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Pattnaik</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rizvi</span>
                           <span tagx="given-names">MM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Improvement in yield and purity of a recombinant malaria vaccine candidate based on
                        the receptor-binding domain of 
                        <i>Plasmodium vivax</i> Duffy binding protein by codon optimization
                     </span>. 
                     <span tagx="source">Biotechnol Lett</span> (
                     <span tagx="year">2006</span>) 
                     <span tagx="volume">28</span>:
                     <span tagx="fpage">1109</span>–
                     <span tagx="lpage">14</span>.
                     <span class="pub-id'">[10.1007/s10529-006-9061-3]</span>
                     <span class="pub-id'">[16794771]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B73"></a>
                  <span class="label">73</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Xainli</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Baisor</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kastens</span>
                           <span tagx="given-names">W</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bockarie</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Adams</span>
                           <span tagx="given-names">JH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">King</span>
                           <span tagx="given-names">CL</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Age-dependent cellular immune responses to 
                        <i>Plasmodium vivax</i> Duffy binding protein in humans
                     </span>. 
                     <span tagx="source">J Immunol</span> (
                     <span tagx="year">2002</span>) 
                     <span tagx="volume">169</span>:
                     <span tagx="fpage">3200</span>–
                     <span tagx="lpage">7</span>.
                     <span class="pub-id'">[10.4049/jimmunol.169.6.3200]</span>
                     <span class="pub-id'">[12218138]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B74"></a>
                  <span class="label">74</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Tran</span>
                           <span tagx="given-names">TM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Oliveira-Ferreira</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Moreno</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Santos</span>
                           <span tagx="given-names">F</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Yazdani</span>
                           <span tagx="given-names">SS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chitnis</span>
                           <span tagx="given-names">CE</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Comparison of IgG reactivities to 
                        <i>Plasmodium vivax</i> merozoite invasion antigens in a Brazilian Amazon population
                     </span>. 
                     <span tagx="source">Am J Trop Med Hyg</span> (
                     <span tagx="year">2005</span>) 
                     <span tagx="volume">73</span>:
                     <span tagx="fpage">244</span>–
                     <span tagx="lpage">55</span>.
                     <span class="pub-id'">[16103583]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B75"></a>
                  <span class="label">75</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Biswas</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Choudhary</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Elias</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Miura</span>
                           <span tagx="given-names">K</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Milne</span>
                           <span tagx="given-names">KH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">De Cassan</span>
                           <span tagx="given-names">SC</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA
                        immunization, controlled human malaria infection and natural exposure
                     </span>. 
                     <span tagx="source">PLoS One</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">9</span>:
                     <span tagx="fpage">e107903</span>.
                     <span class="pub-id'">[10.1371/journal.pone.0107903]</span>
                     <span class="pub-id'">[25254500]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B76"></a>
                  <span class="label">76</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Bouharoun-Tayoun</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Druilhe</span>
                           <span tagx="given-names">P</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">
                        <i>Plasmodium falciparum</i> malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition
                        of protective immunity
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">1992</span>) 
                     <span tagx="volume">60</span>:
                     <span tagx="fpage">1473</span>–
                     <span tagx="lpage">81</span>.
                     <span class="pub-id'">[1548071]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B77"></a>
                  <span class="label">77</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Kapelski</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Klockenbring</span>
                           <span tagx="given-names">T</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Fischer</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Barth</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Fendel</span>
                           <span tagx="given-names">R</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Assessment of the ­neutrophilic antibody-dependent respiratory burst (ADRB) response
                        to 
                        <i>Plasmodium falciparum</i>
                     </span>. 
                     <span tagx="source">J Leukoc Biol</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">96</span>(
                     <div tagxxx="issue">6</div>):
                     <span tagx="fpage">1131</span>–
                     <span tagx="lpage">42</span>.
                     <span class="pub-id'">[10.1189/jlb.4A0614-283RR]</span>
                     <span class="pub-id'">[25118179]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B78"></a>
                  <span class="label">78</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Osier</span>
                           <span tagx="given-names">FH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Feng</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Boyle</span>
                           <span tagx="given-names">MJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Langer</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Zhou</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Richards</span>
                           <span tagx="given-names">JS</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Opsonic phagocytosis of 
                        <i>Plasmodium falciparum</i> merozoites: mechanism in human immunity and a correlate of protection against malaria
                     </span>. 
                     <span tagx="source">BMC Med</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">12</span>:
                     <span tagx="fpage">108</span>.
                     <span class="pub-id'">[10.1186/1741-7015-12-108]</span>
                     <span class="pub-id'">[24980799]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B79"></a>
                  <span class="label">79</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Boyle</span>
                           <span tagx="given-names">MJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Reiling</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Feng</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Langer</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Osier</span>
                           <span tagx="given-names">FH</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Aspeling-Jones</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Human antibodies fix complement to inhibit 
                        <i>Plasmodium falciparum</i> invasion of erythrocytes and are associated with protection against malaria
                     </span>. 
                     <span tagx="source">Immunity</span> (
                     <span tagx="year">2015</span>) 
                     <span tagx="volume">42</span>:
                     <span tagx="fpage">580</span>–
                     <span tagx="lpage">90</span>.
                     <span class="pub-id'">[10.1016/j.immuni.2015.02.012]</span>
                     <span class="pub-id'">[25786180]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B80"></a>
                  <span class="label">80</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Wiley</span>
                           <span tagx="given-names">SR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Raman</span>
                           <span tagx="given-names">VS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Desbien</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bailor</span>
                           <span tagx="given-names">HR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bhardwaj</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shakri</span>
                           <span tagx="given-names">AR</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Targeting TLRs expands the antibody repertoire in response to a malaria vaccine</span>. 
                     <span tagx="source">Sci Transl Med</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">3</span>:
                     <span tagx="fpage">93ra69</span>.
                     <span class="pub-id'">[10.1126/scitranslmed.3002135]</span>
                     <span class="pub-id'">[21795589]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B81"></a>
                  <span class="label">81</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Francica</span>
                           <span tagx="given-names">JR</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sheng</span>
                           <span tagx="given-names">Z</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">Z</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Nishimura</span>
                           <span tagx="given-names">Y</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shingai</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ramesh</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection
                        and protein-plus-adjuvant immunization
                     </span>. 
                     <span tagx="source">Nat Commun</span> (
                     <span tagx="year">2015</span>) 
                     <span tagx="volume">6</span>:
                     <span tagx="fpage">6565</span>.
                     <span class="pub-id'">[10.1038/ncomms7565]</span>
                     <span class="pub-id'">[25858157]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B82"></a>
                  <span class="label">82</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Ceravolo</span>
                           <span tagx="given-names">IP</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sanchez</span>
                           <span tagx="given-names">BA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Sousa</span>
                           <span tagx="given-names">TN</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Guerra</span>
                           <span tagx="given-names">BM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Soares</span>
                           <span tagx="given-names">IS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Braga</span>
                           <span tagx="given-names">EM</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Naturally acquired inhibitory antibodies to 
                        <i>Plasmodium vivax</i> Duffy binding protein are short-lived and allele-specific following a single malaria
                        infection
                     </span>. 
                     <span tagx="source">Clin Exp Immunol</span> (
                     <span tagx="year">2009</span>) 
                     <span tagx="volume">156</span>:
                     <span tagx="fpage">502</span>–
                     <span tagx="lpage">10</span>.
                     <span class="pub-id'">[10.1111/j.1365-2249.2009.03931.x]</span>
                     <span class="pub-id'">[19438604]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B83"></a>
                  <span class="label">83</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Cole-Tobian</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Michon</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Biasor</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Richards</span>
                           <span tagx="given-names">JS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Beeson</span>
                           <span tagx="given-names">JG</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Mueller</span>
                           <span tagx="given-names">I</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Strain-specific Duffy binding protein antibodies correlate with protection against
                        infection with homologous compared to heterologous 
                        <i>Plasmodium vivax</i> strains in Papua New Guinean children
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2009</span>) 
                     <span tagx="volume">77</span>:
                     <span tagx="fpage">4009</span>–
                     <span tagx="lpage">17</span>.
                     <span class="pub-id'">[10.1128/IAI.00158-09]</span>
                     <span class="pub-id'">[19564376]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B84"></a>
                  <span class="label">84</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Sampath</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Carrico</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Janes</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gurumoorthy</span>
                           <span tagx="given-names">S</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gibson</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Melcher</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Glycan masking of 
                        <i>Plasmodium vivax</i> Duffy binding protein for probing protein binding function and vaccine development
                     </span>. 
                     <span tagx="source">PLoS Pathog</span> (
                     <span tagx="year">2013</span>) 
                     <span tagx="volume">9</span>:
                     <span tagx="fpage">e1003420</span>.
                     <span class="pub-id'">[10.1371/journal.ppat.1003420]</span>
                     <span class="pub-id'">[23853575]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B85"></a>
                  <span class="label">85</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Batchelor</span>
                           <span tagx="given-names">JD</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Malpede</span>
                           <span tagx="given-names">BM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Omattage</span>
                           <span tagx="given-names">NS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Dekoster</span>
                           <span tagx="given-names">GT</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Henzler-Wildman</span>
                           <span tagx="given-names">KA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Tolia</span>
                           <span tagx="given-names">NH</span>,
                        </span>
                     </span>. 
                     <span tagx="article-title">Red blood cell invasion by 
                        <i>Plasmodium vivax</i>: structural basis for DBP engagement of DARC
                     </span>. 
                     <span tagx="source">PLoS Pathog</span> (
                     <span tagx="year">2014</span>) 
                     <span tagx="volume">10</span>:
                     <span tagx="fpage">e1003869</span>.
                     <span class="pub-id'">[10.1371/journal.ppat.1003869]</span>
                     <span class="pub-id'">[24415938]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B86"></a>
                  <span class="label">86</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Siddiqui</span>
                           <span tagx="given-names">AA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Xainli</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Schloegel</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Carias</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Ntumngia</span>
                           <span tagx="given-names">F</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Shoham</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Fine specificity of 
                        <i>Plasmodium vivax</i> Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes
                     </span>. 
                     <span tagx="source">Infect Immun</span> (
                     <span tagx="year">2012</span>) 
                     <span tagx="volume">80</span>:
                     <span tagx="fpage">2920</span>–
                     <span tagx="lpage">8</span>.
                     <span class="pub-id'">[10.1128/IAI.00206-12]</span>
                     <span class="pub-id'">[22615246]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B87"></a>
                  <span class="label">87</span>
                  <div tagxxx="mixed-citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Russell</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Suwanarusk</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Borlon</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Costa</span>
                           <span tagx="given-names">FT</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Chu</span>
                           <span tagx="given-names">CS</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rijken</span>
                           <span tagx="given-names">MJ</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">A reliable ex vivo invasion assay of human reticulocytes by 
                        <i>Plasmodium vivax</i>
                     </span>. 
                     <span tagx="source">Blood</span> (
                     <span tagx="year">2011</span>) 
                     <span tagx="volume">118</span>:
                     <span tagx="fpage">e74</span>–
                     <span tagx="lpage">81</span>.
                     <span class="pub-id'">[10.1182/blood-2011-04-348748]</span>
                     <span class="pub-id'">[21768300]</span>
                  </div>
               </li>
            </ul>
         </div>
      </div>
   </div>
</html>